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Pathogens like bacteria, viruses and parasites represent a constant threat to the human 
body. The immune system is the body’s natural defense to these pathogens, as well as to 
other threats such as the outgrowth of tumor cells.
The immune system can be divided into two arms, the innate and the acquired immune 
system. The innate immune system consists of physical barriers such as the skin and the 
mucosa, but also a set of soluble factors in blood that are able to bind to pathogens and 
lead to inactivation of the pathogen, collectively called the complement system (1, 2). The 
innate immune system also includes receptors, such as Toll Like Receptors (TLR) that 
recognize patterns specific for pathogens (3). Moreover, there are cells within the innate 
immune system, such as phagocytic cells (granulocytes and macrophages), which internal-
ize and kill pathogens (4) and natural killer (NK) cells, which respond to cells lacking a sign 
identifying them as being ‘self’ (5).
The acquired immune system comprises a repertoire of cells that is generated upon anti-
genic challenge and thus depends on the individual’s exposure to pathogens. All cells that 
acquire memory after the encounter of a pathogen are considered to be of the acquired 
immune system. These cells bear receptors on their cell surface that provide specificity. 
Cells that encounter a certain pathogen for the first time are called naïve cells. These cells 
will expand and mature into effector cells and memory cells. These memory cells are ca-
pable of rapidly responding in case of a subsequent encounter with the same pathogen (6). 
Cells of the acquired immune system include T cells that provide cellular immunity and B 
cells that provide humoral immunity.
In case a person’s immune system is not able to adequately respond to an infection, the 
individual can succumb to the infection. This is very well illustrated by patients suffering 
from AIDS, who do not have a functional immune system and often die of complications 
of (normally non life-threatening) infections such as pneumocystis pneumonia (7). On the 
other hand, if the immune system is responding too vigorously or fails to be regulated, this 
can lead to allergies and/or autoimmune diseases (8).
THE MAJOR HISTOCOMPATIBILITY COMPLEX
T cells constantly survey the body for the presence of pathogens. For T cells to be able to 
recognize the presence of foreign structures, they express a polymorphic receptor, called 




tides only when they are presented in molecules of the major histocompatibility complex 
(MHC) (9-11). This phenomenon, preventing T cells to respond in an uncontrolled fashion, 
is called MHC restriction. MHC molecules are present on virtually all cells of vertebrated 
animals. In humans, the polymorphic system of MHC molecules is called the human leu-
kocyte antigen (HLA) system and was originally demonstrated by the use of agglutinating 
antibodies in the sera of patients who had undergone multiple blood transfusions and of 
multiparous women (12-14).
HLA class I
There are two classes of HLA molecules, both with similar, yet distinct functions. The HLA 
class I molecules, encoded by the HLA-A, HLA-B and HLA-C genes, are present on all 
nucleated cells and platelets. HLA class I molecules consist of a heavy chain, a light chain 
and a peptide. The 44kD heavy chain (α chain) is encoded on chromosome 6 (15) and is 
non-covalently associated with a 12 kD light chain called β2-microglobulin (β2m), which is 
encoded on chromosome 15 (16, 17). The α chain consists of 3 extracellular domains (α1, 
α2 and α3), a transmembrane region and a cytoplasmic tail (Figure 1). The polymorphism of 
the HLA class I molecules is based on differences in amino acid sequences in the α1 and α2 
domains (18). The function of HLA class I molecules is to present endogenously generated 
peptides (19). Proteins are degraded into peptides by the proteasome (20) and some of 
these peptides are subsequently loaded onto HLA molecules in the endoplasmic reticulum 
after which the HLA-peptide complexes are transported to the cell surface (19). These 
peptides are in general 8-13 amino acids in length (21-23). 
In case of an infection, HLA class I molecules can present peptides originating from the 
intracellular pathogen to CD8+ cytotoxic T lymphocytes (CTL), which can subsequently 
eliminate the infected cell (24). Thus, HLA class I molecules enable the immune system to 
survey the intracellular space.
HLA class II
HLA class II molecules are less widely distributed than class I molecules and are mainly 
found on professional antigen presenting cells (APCs), such as monocytes, dendritic cells 
(DC), macrophages and B cells, but also on endothelial cells and activated T cells. They are 
encoded by the HLA-DP, HLA-DQ and HLA-DR genes. HLA class II molecules are formed 
by 2 non-identical chains, called the α chain (32 kD) and the β chain (28 kD), both encoded 
on chromosome 6 (25), and a peptide. HLA class II molecules consist of an extracellular 
part (with domains α1, α2, β1 and β2), a transmembrane region and a cytoplasmic part 
(Figure 1) (26, 27). The polymorphism of HLA-DR lies in the β1 chain, while for HLA-DP 
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and DQ the polymorphism resides in both the α1 and the β1 chain. The function of HLA 
class II molecules is to present peptides from proteins that were taken up from the extra-
cellular environment to CD4+ helper T cells (28). To this end, proteins are digested into 
peptides in the lysosomal compartment and loaded into the HLA class II peptide binding 
cleft (19). These peptides are typically 13-25 amino acids long (29-32). The HLA-peptide 
complex is transported to the cell surface where it can be recognized by CD4+ T cells. This 
mechanism is utilized by the adaptive immune system so survey the extracellular space for 
pathogens.
ALLORECOGNITION
The enormous degree of polymorphism in HLA is essential for survival of the species. As 
a consequence of the diversity in HLA molecules (having distinct binding motifs), different 
peptides can be presented by different HLA molecules in different individuals. The diver-
sity in pathogen-derived peptides that can be presented in the population ensures that in 
Figure 1. The structure of HLA molecules. HLA class I (left) consists of a heavy chain (α chain) and a light chain (β
2
m). 















case of an endemic infection, the chance of at least some individuals capable of coping with 
the infection is relatively high. For example, susceptibility to HIV and disease progression 
has been linked to certain HLA types (33). Furthermore, sustained presence of a pathogen 
can lead to a relative increase of certain HLA types in a population. This is nicely illustrated 
in relation to Malaria susceptibility. The class I allele HLA-B53 is associated with resistance 
to Malaria. Consequently, in West Africa, where Malaria infections have a high prevalence, 
a high frequency of HLA-B53 occurs (34).
A consequence of their polymorphism is that HLA molecules themselves can be recog-
nized by the immune system as foreign, a phenomenon called allorecognition. Conse-
quently, HLA molecules represent a huge hurdle in solid organ, islet and bone marrow 
transplantation as well as blood transfusion. Because of the high degree of polymorphism 
of HLA, the chance that unrelated donors and recipients have identical HLA molecules is 
very small (35). Recognition of foreign HLA by T cells can take place in two different ways 
as described below.
Direct allorecognition
When an organ is transplanted, donor immune cells bearing mismatched HLA class II 
molecules (mainly DC), can be recognized via the direct allorecognition pathway (Figure 
2). In this route of allorecognition, T cells of the recipient directly recognize intact foreign 
HLA molecules and can initiate a vigorous immune response (36, 37). The peptide that is 
presented within the donor MHC may not necessarily be allogeneic, but often seems to 
be derived from donor MHC molecules and thereby increases immunogenicity (38, 39).
Indirect allorecognition
Later after transplantation, when donor antigen presenting cells are no longer present, 
peptides originating from the donor organ can only be presented by professional antigen 
presenting cells from recipient origin (Figure 2). Since this involves foreign peptides in the 
context of self-MHC, it is referred to as the indirect route of allorecognition (36, 40-42). 
This is the physiological way of the immune system to present and recognize foreign an-
tigens. Evidently, indirect allorecognition will also take place early after transplantation.
Given the great diversity in HLA molecules and knowing the consequences of the immune 
response following allorecognition, it is very important to achieve the highest degree of 
homology between donor and recipient as possible. Therefore, optimizing the HLA match 
of donor organs with prospective recipients has proven to be of great benefit in terms of 
graft survival (43-46). However, since a complete match can only be achieved in monozy-





A transplanted organ can be subject of rejection throughout its presence in the recipient. 
Firstly, when there are specific pre-existing antibodies, either towards ABO blood group 
antigens (47) or foreign HLA (48) on the donor organ, it can be destroyed within the 
first 24 hours after transplantation. This phenomenon is called hyperacute rejection. The 
pre-existing antibody repertoire towards HLA can be either due to blood transfusions, 
previous transplants or pregnancies (49-52). To determine if the patient has preformed 
donor-specific antibodies, serum of the patient is routinely tested by incubation with cells 
from the donor prior to transplantation. When the test is positive, the transplantation will 
not be performed. Since the introduction of this pre-transplant serological crossmatching, 

















Figure 2. The direct and the indirect pathway of allorecognition. Direct allorecognition (left) involves recognition of 
mismatched donor HLA on donor antigen presenting cells (APCs), regardless of the peptide presented. Indirect allorecog-






Acute cellular rejection occurs in the first months after transplantation and is mainly 
caused by the direct route of alloantigen presentation. The magnitude of this immune 
response is likely caused by the high precursor frequency of T cells that recognize intact 
HLA molecules (54, 55). The majority of patients receiving a graft undergo one or more 
acute rejection episodes, which, in general, are effectively treated with immunosuppres-
sive drugs as discussed below.
Another form of acute rejection, acute humoral rejection, can occur in patients who have 
been sensitized to a certain antigen but have undetectable donor-specific antibody levels 
at time of transplantation. When transplanted, memory B cells can rapidly initiate the pro-
duction of antibodies directed against the donor organ. Besides early acute rejection, both 
acute cellular and humoral rejection can occur late after transplantation, mostly due to 
noncompliance to medication by the transplanted patient (56). Both types of acute rejec-
tion can occur individually, but may coincide.
Chronic rejection
Finally, a transplanted organ can be subject to a process of slow deterioration, resulting 
usually from a multi-factorial process caused by a combination of non-immunological and 
immunological damage (57). The pathological image seen in kidney transplants that have 
been suffering from such multi-factorial damage, usually over a period of many years, is 
termed chronic allograft nephropathy (CAN). The term CAN indicates presence of chron-
ic tissue damage, and is used in those cases where the underlying cause of the chronic 
transplant dysfunction is not clear (58). The term CAN has recently been replaced by 
interstitial fibrosis and tubular atrophy (IFTA). The major cause of non-immunologic organ 
damage is toxicity of immunosuppressive medication (59). The underlying immunologic 
process is characterized by a chronic alloreactive immune response, called chronic rejec-
tion. The main immunologic mechanism associated with antibody formation is thought to 
be the indirect pathway of alloantigen presentation (60). Treatment of CAN or chronic 
rejection is not as standardized as for acute rejection and appears to be less effective (61).
Cellular and humoral rejection
Classically, rejection has been considered to be a T cell mediated process (cellular rejec-
tion), mainly because in early mice studies, transfer of cells but not serum could initiate 
graft rejection (62). However, the contribution of humoral immunity is increasingly recog-
nized (63, 64). When rejection is caused by alloantibodies, it is referred to as humoral re-
jection or antibody mediated rejection. The important role of antibodies in rejection was 
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shown in studies where formation of anti-donor antibodies regularly preceded chronic 
rejection of kidney transplants (65-67). 
Next to serum alloantibodies, a hallmark for the diagnosis of humoral rejection is the 
presence of the complement split-product C4d in the kidney (68). When tissue-bound 
alloantibodies fix complement factor C1q, a cascade of reactions is initiated, resulting in 
binding of the split-product C4d to the tissue. There is a strong correlation between the 
presence of anti-donor HLA antibodies and C4d positivity (69), although C4d positivity 
without HLA-specific antibodies can occur in the case of non anti-HLA donor specific 
antibodies and anti-HLA specific antibodies without C4d positivity can be present in the 
case of non complement fixing alloantibodies. Peritubular capillary (PTC) deposition of 
C4d was a predictor of inferior 12-month graft function (70), underscoring the importance 
of humoral immunity in transplantation.
ANTIBODIES AND B CELLS
Antibodies
The importance of the humoral immune system is clear from inherited B cell deficiencies, 
such as X-linked agammaglobulinemia, where patients lack antibody production and there-
fore repeatedly acquire infections with certain bacteria and viruses, which can potentially 
be lethal (71).
Antibodies (soluble proteins, also known as immunoglobulins) consist of two identical 
light polypeptide chains and two identical heavy polypeptide chains. These chains form 
a homodimer with an antigen binding region (Fab) and a crystallizable region (Fc) per 
subunit (Figure 3) (72). The Fab fragment is responsible for binding to foreign structures 
and harbors antigenic specificity, whereas the Fc part determines the effector function of 
the antibody. There are nine different Fc parts, called isotypes (IgM, IgD, IgG1-IgG4, IgA1, 
IgA2 and IgE). Antibodies of the IgM isotype are most effective in activating a cascade of 
complement pro-enzymes, resulting in phagocytosis and killing of microorganisms (73). 
IgG antibodies (mainly IgG1 and IgG3) are effective in activating complement, as well as 
opsonization of antigens (74). Furthermore, binding of antibodies of IgG1 and IgG3 isotypes 
can result in target cell lysis by antibody dependent cytotoxicity (ADCC), brought about 
by NK cells upon engagement of their Fc receptor (FcγRIII) with these antibodies (63, 
75). IgA antibodies are mainly present in mucous membranes to prevent infections via the 
intestinal and respiratory tract, whereas IgE antibodies are very efficient in triggering eo-





Antibodies formed against a transplanted organ (mainly IgM and IgG) can have deleterious 
effects, as antibodies can cause damage of the endothelium lining the blood vessels of the 
transplanted organ (76). Platelets subsequently aggregate and this clotting will deprive the 
organ from oxygen, leading to necrosis of the organ (77). 
B cells
B cells have the unique property of bearing antibodies on their cell membrane that act as 
receptors for recognition of foreign structures. This receptor is called the B cell recep-
tor (BCR). Antigens are recognized by the BCR in a MHC unrestricted fashion, which 
is distinct from TCR recognition. Upon binding of the BCR, the bound antigen can be 
internalized and enter the MHC class II presentation pathway (78). This makes the B cell 
a potent antigen presenting cell capable of activating T cells (79-81). When a helper T cell 
Figure 3. Schematic representation of an antibody. Antibodies consist of two heavy chains (grey) and two light chains 
(white). The variability of antibodies lies in the Fab part, which gives rise to the antigen-binding site. The functionality 









recognizes the presented peptide in this MHC restricted fashion, it gets activated. The T 
cell subsequently activates the B cell, resulting in immunoglobulin class switch, antibody 
production and memory B cell and plasma cell formation. Plasma cells are fully differenti-
ated B cells that have lost their BCR and have the sole function of producing large quanti-
ties of antibodies.
Key molecules in the interaction between B cells and T cells are obviously HLA class II and 
the T cell receptor, but also costimulation by e.g. CD40 – CD40L interactions is essential 
(Figure 4) (82). Furthermore, cytokines produced by T cells play an important role in the 
activation and fate of the B cell. For example, the presence of IL-4 leads to isotype switch-
ing towards IgE producing B cells (83), whereas IL-5 skews towards IgA producing B cells 
(84) and IFN-γ towards IgG2a (85).
B cells are formed in the bone marrow where early pro-B-cells carrying no antigen re-
ceptor develop into antigen receptor carrying mature B cells in an antigen independent 
fashion (73). Initial B cell activation can occur in various, non-exclusive, manners. Antigen 
recognition by the BCR will provide an activation signal to B cells, but also ‘danger’ signals 
in the form of TLR ligands play an important role in B cell activation (86). BCR crosslinking 
leads to rapid upregulation of TLR9 in naïve B cells, allowing for an additional activation 
signal (87, 88). This initial activation usually occurs in the T cell zone of lymphoid organs by 
interaction with T helper cells and dendritic cells (89). Following activation, B cells migrate 
into B cell follicles, proliferate and establish germinal centers (Figure 5) (90, 91). There, so-
matic hypermutation occurs, which involves random mutations in the genes encoding the 
recognition sites on antibodies, giving rise to B cells with a spectrum of antigen-affinities 
(92). Only B cells that have gained an increased affinity for the antigen will survive due to 
interaction with follicular dendritic cells (FDC) and germinal center T cells (93). Following 
this interaction, B cells will undergo several rounds of proliferation, mutation and selec-
tion. Furthermore, isotype switching can occur, leading to B cells that produce antibodies 
with specific functions (94). Finally the B cells develop into memory B cells (95) and plasma 
cells (96). The majority of plasma cells will migrate to the bone marrow, where they sur-
vive as long-lived plasma cells (97). 
In vitro B cell activation
The in vitro activation of purified B cells can be achieved in various ways leading to pheno-
typically and functionally different cells. In principle, one can make use of (a combination 
of) the three natural stimulatory signals for B cells; BCR ligation, TLR signaling and T cell 
help.




property of binding the Fc part of the BCR, has been used frequently (98), as well as 
agonistic antibodies directed against the BCR (99). The addition of a TLR9 ligand, un-
methylated CpG DNA, has been described to synergize with cognate T cell help and BCR 
triggering (88). Recombinant molecules, such as soluble CD40L or anti-CD40 monoclo-
nal antibody (mAb), can mimic T cell help (100). Cell lines expressing CD40L on the cell 
surface are also used as surrogate for T cells (101, 102). Obviously, the addition of B cell 
stimulatory cytokines such as IL-2, IL-4, IL-10 and IL-21 is often used to get optimal B cell 
activation and differentiation (99, 103, 104). Furthermore, mitogenic signals activating lec-
tin pathways such as Pokeweed Mitogen (PWM) have been frequently used, although this 
is a stimulus that requires T cell help (105).
CD40L      CD40
ICOS  ICOSL
CD28 CD80/CD86






TCR     MHC II
T cell
antigen
Figure 4. T – B cell interaction. Following antigen recognition, the B cell internalizes the antigen and, after processing, 
presents the antigen to T cells. Upon encounter of a T cell with the right specificity, the B stimulates the T cell to up-
regulate stimulatory molecules at the cell surface and produce B cell activating cytokines. BCR: B cell receptor, ICOS: 




Every transplant recipient is treated with immunosuppressive drugs to minimize the 
chance of rejection. These immunosuppressive drugs must generally be taken for the rest 
of the patient’s life. At time of transplantation, most patients are conditioned to make sure 
that the most vigorous immune response is prevented. The conditioning regiment varies 
between transplant centers. Often, conditioning is achieved by the use of depleting anti-
bodies (e.g. anti-thymocyte globulin, ATG), leading to the depletion (of subsets) of lympho-
cytes (106, 107). After transplantation, patients receive maintenance immunosuppression 
typically consisting of a combination of a calcineurin inhibitor and corticosteroids with or 
without the addition of proliferation or mTOR (mammalian target of rapamycin) inhibitors. 
These immunosuppressive drugs mainly target the T cell response, while B cell priming 

























Figure 5. The germinal center reaction. In the dark zone of the germinal center, B cells undergo clonal expansion and 
somatic hypermutation. B cells with increased affinity for the antigen undergo further differentiation and class swiching in 
the light zone. Finally the B cells become either memory B cells or plasma cells. FDC: follicular dendritic cell (adapted from 




it is the type of the rejection that determines the treatment. Cellular rejection is mostly 
treated with corticosteroids, with ATG as a second-line therapy. Treatment of humoral 
rejection is more difficult and is still not standardized. Protocols including plasmapheresis, 
intravenous immunoglobulin (IVIg) and the B cell depleting chimeric mAb Rituximab have 
been described (108-111). More recently, a drug targeting plasma cells (bortezomib) has 
been described for treatment of humoral rejection (112).
The use of immunosuppressive drugs in organ transplantation is inevitable, and unfortu-
nately has major side effects. Drug toxicity (59), the increased susceptibility to infections 
(113), increased tumor incidence (114) and cardiovascular disease (115) are major concerns 
when administering immunosuppressive drugs. Therefore, minimizing the dose of immuno-
suppressive drugs is essential and the search for more specific immunosuppressive drugs 
is needed (116, 117). In the following section, commonly used immunosuppressive drugs 
will be looked at in further detail, as well as experimental drugs that are described in this 
thesis.
Calcineurin inhibitors
The introduction of cyclosporin in the early 80’s (in combination with the anti-CD3 mAb 
OKT3) into the clinic initiated a new era in solid organ transplantation. The one-year 
graft survival increased from 60% up to 90% (118, 119). Cyclosporin, as well as tacrolimus 
(FK506), is a calcineurin inhibitor, mainly affecting the activation of T cells. 
When a T cell gets activated via its TCR, the intracellular Ca2+ levels are increased. There-
upon, the phosphatase calcineurin gets activated and subsequently activates the cytoplas-
mic form of members of the family of nuclear factors of activated T cells (NFAT). Activated 
NFAT enters the nucleus and initiates gene transcription of several genes, including the 
IL-2 gene. Cyclosporin binds to the intracellular protein cyclophilin (CyP), and tacrolimus 
to FK506-binding protein (FKBP). Both complexes subsequently bind to calcineurin, pre-
venting it from activating NFAT (120, 121). In this manner, transcription of several genes 
that are expressed upon activation is suppressed.
Corticosteroids
Corticosteroids, such as prednisone, are used in transplantation as maintenance therapy 
as well as to revert (cellular) rejection. Corticosteroids are powerful anti-inflammatory 
drugs that bind to intracellular steroid receptors (122). This complex can cross the nuclear 
membrane and bind to specific gene regulatory sequences, and thereby modulate the tran-
scription of numerous genes (123). This leads to a great number of effects, of which the 




At the present time, the anti-proliferative drug commonly used in clinical protocols is 
Mycophenolate Mofetil (MMF). MMF is metabolized in the liver into Mycophenolic Acid 
(MPA), which inhibits the enzyme inosine-5’-monophosphate dehydrogenase (IMPDH). 
This enzyme is involved in the de novo pathway of purine synthesis. By inhibiting this en-
zyme, MPA is able to inhibit DNA synthesis of lymphocytes. This effect is rather specific 
for lymphocytes because cells other than lymphocytes can obtain purines by the salvage 
pathway (124).
mTOR inhibitors
Rapamycin, like tacrolimus, binds to FKBP. However, this complex does not bind to cal-
cineurin, but to the mammalian target of rapamycin (mTOR). This is a serine/threonine 
protein kinase involved in a number of cellular processes, such as proliferation, cell survival 
and protein synthesis. mTOR is downstream of multiple signaling pathways and responds 
to nutrient concentrations, growth factors, mitogens and cytokines, like IL-2 (125). Block-
ing the mTOR pathway by rapamycin thus leads to a general suppression of lymphocyte 
activity.
IVIg
IVIg is a pool of plasma obtained from at least 1000 healthy donors. These large numbers 
of donors assure that IVIg consists of a repertoire of antibodies that represents the com-
plete population (126). IVIg has originally been used as substitution therapy for patients 
with immunodeficiency diseases (127). The therapeutic area widened when it was dis-
covered that IVIg was beneficial to patients suffering from various autoimmune diseases 
(128). Finally, IVIg is also used in transplantation settings in efforts to decrease the level of 
alloantibodies (129-131) and to treat humoral rejection (108, 109).
The mechanism of action of IVIg is incompletely understood, but its actions are thought 
to be manyfold. First of all, because of the administration of high doses immunoglobulins, 
the natural metabolism of immunoglobulins through the neonatal Fc receptor (FcRn) may 
be enhanced (132). This can lead to clearance of pathogenic antibodies (133). Furthermore, 
anti-idiotypic antibodies contained within the IVIg can bind to autoantibodies, and there-
fore may limit tissue damage in certain autoimmune disorders (134). In transplantation, 
anti-idiotypic antibodies may interfere in the reaction of HLA-specific antibodies with 
their targets on HLA mismatched organs, thereby preventing humoral rejection (135, 136). 
Moreover, anti-idiotypic antibodies have been suggested to bind to B cell receptors result-




IVIg may also bind through the Fc portion of IgG to the inhibitory FcγRIIb (CD32) ex-
pressed on a variety of blood cells, including B cells, leading to the reduction of prolif-
eration and the induction of apoptosis (139). IVIg may directly inhibit complement, and 
thereby modulate the effector function of antibodies (140, 141). Furthermore, IVIg may 
contain antibodies directed against cytokines and thereby limit their action (142). The pos-
sible presence of soluble HLA in IVIg may be of benefit for the immunized patient, as it may 
neutralize HLA-specific antibodies (143).
Bortezomib
The proteasome inhibitor bortezomib was originally used for the treatment of refrac-
tory multiple myeloma, a plasma cell neoplasia (144). Recently, the use of bortezomib as 
an agent for targeting allo-antibody producing plasma cells has received major interest 
(112, 145, 146). Bortezomib selectively inhibits the proteasome, an intracellular protease 
responsible for degrading misfolded proteins, as well as quick-turnover signaling proteins. 
When the proteasome is blocked, unfolded proteins accumulate, leading to apoptosis (147, 
148). Moreover, the anti-apoptotic transcription factor NF-κB relies on the proteasome 
to be active (149). Since antibody producing cells have an extremely high protein turnover, 
these cells potentially are extremely sensitive to proteasome inhibition. Hence, bortezo-
mib may present the long-sought after drug to treat humoral rejection.
AIM OF THIS THESIS
Whereas the short-term transplant survival is excellent at the present time, mainly be-
cause of potent immunosuppression, the long-term graft and patient survival is still a field 
in need of improvement. Two mechanisms are of importance regarding chronic rejection. 
Firstly, the involvement of the humoral arm of the immune system in rejection pathology 
is increasingly appreciated, particularly in chronic humoral rejection pathology. In 61% of 
renal transplant patients experiencing late allograft dysfunction a positive C4d staining 
was found, indicating the involvement of humoral immunity (150). Furthermore, in case 
of chronic rejection, HLA-specific antibodies are frequently detected prior to rejection, 
suggesting a causative role of antibody formation (65). 
Secondly, in later phases after transplantation, the indirect route of allorecognition is the 
main pathway in which T cells get activated and can compromise graft integrity. Moreover, 
B cells involved in chronic rejection most likely receive T cell help from T cells that indi-
rectly recognize alloantigens. 
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The studies described in this thesis are aimed to shed light on which immunusuppressive 
drugs, both standard drugs and experimental drugs, are suitable to inhibit humoral im-
mune responses. Moreover, as described in this thesis, monitoring of both HLA-specific B 
cells and the indirect pathway of allorecognition are important to identify patients at risk 
for rejection and patients who are eligible for tapering of immunosuppressive drugs. 
Since there is no specific treatment for (chronic) humoral rejection to date, it is generally 
treated with standard, non-specific immunosuppressive drugs. It is important to know 
which immunosuppressive drug is most potent in inhibiting humoral responses. Therefore, 
we studied the direct effects of standard immunosuppressive drugs on purified B cells in 
vitro, described in chapter 2, as well as the effects of immunosuppressive drugs on T cell 
help and B cells in the presence of T cell help, described in chapter 3.
One of the ways that is currently pursued to overcome the problems of pre-existing 
antibodies and humoral rejection is the use of IVIg (151, 152). However, little solid data 
exists on how IVIg would exert its beneficial effect in the setting of transplantation. We 
tested whether IVIg was able to affect key B cell responses in an in vitro culture system as 
described in chapter 4. In addition, we determined whether the anti-plasma cell agent 
bortezomib was also effective in targeting B cell responses, thereby broadening its thera-
peutic potential. These studies are described in chapter 5.
we have developed a novel technique to quantify the antigen specific peripheral B cell load 
in an individual, described in chapter 6. Using this technique, it is possible to monitor the 
HLA-specific B cell activity of a given patient in time, allowing for correlation with clinical 
parameters and aiding in the determination of tailor-made immunosuppressive regimens.
Late after transplantation, monitoring of alloreactive T cells that indirectly recognize 
foreign HLA may provide insight on the humoral alloimmune status, since T cell help is 
important for developing B cell responses. However, the exact contribution of indirect 
allorecognition to rejection is not known and has proven to be difficult to study. In chap-
ter 7, attempts at the development of a reliable assay to monitor indirect allorecognition 
are described, along with a critical literature review of the articles that claim to have iden-
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Humoral immunity is increasingly recognized as an important factor in the rejection of organ 
transplants. In general, humoral rejection is treated with standard immunosuppressive 
drugs. The direct effect of these immunosuppressive drugs on B cells is not well known.
Purified human B cells devoid of T cells were stimulated with either CD40L expressing L 
cells, or by anti-CD40 mAb with or without TLR triggering, all in the presence of B cell 
activating cytokines. These three protocols resulted in various degrees of B cell stimulation. 
We added four commonly used immunosuppressive drugs (tacrolimus, cyclosporin, MPA 
and rapamycin) to these cultures and tested a variety of parameters of B cell activity 
including proliferation, apoptosis induction and both IgM and IgG production.
Tacrolimus and cyclosporin marginally inhibited B cell proliferation and immunoglobulin 
production, and the extent of inhibition depended on the degree of the B cell stimulation. 
In contrast, MPA and rapamycin profoundly inhibited both B cell proliferation and 
immunoglobulin production, which was independent of the degree of B cell stimulation. 
Both drugs induced B cell apoptosis. Moreover, rapamycin caused a reduction of the 
number of B cells capable of producing immunoglobulins. 
Our data show that MPA and rapamycin are capable of strongly inhibiting B cells responses. 
This provides a rationale for the use of both MPA and rapamycin to prevent and/or 
counteract humoral responses.
 




When an organ is transplanted in a major histocompatibility complex noncompatible 
recipient, it can elicit an immune response. To achieve long-term graft survival with a 
fully functional graft, this immune reactivity needs to be suppressed. To this end potent 
immunosuppressive drugs have been developed. The downside of these non-specific 
immunosuppressants is their toxicity (1), the increased susceptibility to infections (2) and 
an increased tumor incidence (3). Therefore, minimizing the dose of immunosuppressive 
drugs is pivotal.
The impact of humoral immunity towards mismatched donor antigens was obvious from 
hyperacute rejection, where preformed anti-HLA or ABO antibodies destroyed the 
graft within minutes after transplantation (4). Such preformed antibodies are induced 
by pregnancies, blood transfusions or previous transplants. With the practice of pre-
transplant serologic crossmatching, the occurrence of hyperacute rejection has become 
extremely rare (5). For a long time, T cells were considered the prime contributors to 
acute rejection. Therefore, immunosuppressive therapies for prevention or treatment of 
graft rejection so far have been mainly targeted towards T cells. However, both acute and 
chronic rejection can be antibody-mediated as well (6).
The only B cell specific agent that is currently in clinical use is Rituximab, a B cell depleting 
monoclonal antibody of which varying results in transplantation have been published (7, 8). 
Therefore, lacking B cell specific drugs with proven efficacy in transplantation, clinicians 
at the present time mostly treat antibody-mediated rejections with immunosuppressive 
therapies that are not specifically targeting the humoral immune system. 
There are indications that standard immunosuppressive drugs have effects on humoral 
immunity. Cyclosporin was superior to azathioprine in suppressing the development of 
protective antibody titers following influenza vaccination post transplantation (9). Similar 
studies show a profound inhibitory effect of MMF and rapamycin on the formation of 
influenza-specific antibodies (10, 11). These studies provide information on the reduction 
of antibody production, but whether the drugs studied affect B cells directly is not known. 
The present study has been performed to gain insight on the direct effects of currently 
used immunosuppressive drugs on a variety of B cell parameters including proliferation, 





Blood was obtained from blood bank donors after informed consent. Peripheral blood 
mononuclear cells (PBMC) were isolated by Ficoll Hypaque density gradient centrifugation. 
B cells were immunomagnetically isolated from PBMC by positive selection using Dynabeads 
CD19 pan B (Dynal, Oslo, Norway). The CD19-positive cells were released from the beads 
using Detach-a-Bead CD19 (Dynal). This typically yielded >98% pure B cells, as assessed 
by staining with a FITC-conjugated CD19 mAb (BD Biosciences, Breda, the Netherlands) 
followed by flow cytometric analysis (FCM).
Culture conditions
B cell cultures were done in culture medium consisting of IMDM (Gibco, Paisley, UK) 
supplemented with 10% FCS (Gibco), 0.05 mM 2-mercaptoethanol (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) and ITS (insulin, transferrin and selenium, Sigma-Aldrich, 
1000 fold diluted). B cells were cultured with 3 different stimuli at 37ºC in a 5% CO2 
humidified incubator. The first stimulus consisted of irradiated (75 Gy) L-CD40L cells with 
100 U/ml IL-2 (EuroCetus, Amsterdam, the Netherlands), 25 ng/ml IL-10 (R&D systems, 
Minneapolis, MN, USA) and 100 ng/ml IL-21 (Invitrogen, Leek, the Netherlands). The 
second stimulus consisted of an anti-CD40 mAb (1 µg/ml, R&D systems) combined with IL-
2, IL-10, IL-21 (concentrations as above) and 2.5 µg/ml of the TLR9 ligand CpG ODN 2006 
(Hycult Biotechnology, Uden, the Netherlands). Finally, the third stimulus was identical to 
the second, but lacking the ODN-2006 CpG.
Immunosuppressive drugs
Tacrolimus (Prograf, Astellas, Leiderdorp, the Netherlands, diluted in absolute ethanol) 
and cyclosporin (Sandimmune, obtained as a solution, was from Novartis, Arnhem, the 
Netherlands) were used at final concentration ranges of 0-1 ng/ml and 0-100 ng/ml, 
respectively. We based these concentration ranges on published plasma trough levels at 
6 months post-transplantation (12-14). Calcineurin inhibitor concentrations reported for 
whole blood are considerably higher, but it should be noted that a substantial fraction of 
these drugs are bound to erythrocytes (15, 16), which are not present in our cultures. 
Mycophenolic acid (MPA, Sigma-Aldrich, Zwijndrecht, the Netherlands), the active 
metabolite of MMF, was dissolved in ethanol and used in concentrations up to 100 ng/ml, 
which is approximately 10-fold lower than used in the clinic. This concentration range was 
chosen because a maximal effect was already observed using 100 ng/ml in some experiments 
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and the limitation of low cell yields in other experiments. Rapamycin (Calbiochem, La Jolla, 
CA, USA) was dissolved in methanol and used in concentrations up to 8 ng/ml. Working 
solutions of all immunosuppressive drugs were made in culture medium.
Proliferation assay
B cells were seeded at 5×103 cells per well in 96-wells round bottom plates (BD Falcon, 
Breda, the Netherlands) and cultured with the stimuli described above (first stimulus with 
103 L-CD40L cells) in the presence of increasing concentrations of immunosuppressive 
drugs, either added directly or after 48 h. At day 6, supernatants were collected for 
immunoglobulin detection and 1 µCi 3H-TdR (Amersham International, Amersham, United 
Kingdom) was added per well for the last 18 h of culture. 3H-TdR incorporation was 
measured using a liquid scintillation counter (Wallac, Turku, Finland).
Immunoglobulin Production
Supernatants harvested from proliferation experiments were tested for IgM and IgG levels 
with a standard sandwich ELISA. Plates (Greiner, Alphen a/d Rijn, the Netherlands) were 
coated overnight with a goat anti-IgG or anti-IgM (Jackson Immunoresearch, Westgrove, 
PA, USA) diluted in 10 mM Tris pH 9.0, then were blocked with 2% bovine serum albumin 
(BSA, Sigma-Aldrich) in 0.025% Tween-20 (Sigma-Aldrich) in PBS (PBS-T). Fifty µl of 
supernatants or standard human serum (Sanquin, Amsterdam, the Netherlands) in a serial 
dilution were incubated for 60 min at 37°C. After washing with PBS-T, biotin labeled 
goat anti-IgM or anti-IgG (Biosource, Camarillo, CA, USA) diluted in 1% BSA/PBS-T was 
incubated for 60 min at 37°C. After extensive washing, streptavidin horseradish peroxidase 
(Pierce, Rockford, IL, USA), diluted in 1% BSA in PBS-T was added and incubated for 60 min 
at 37°C. A color reaction was obtained with 4.6 mM 2,2’-azine-bis(3-ethylbenzthiazoline-
6-sulfonic acid) (ABTS, Sigma-Aldrich) in a citric acid / PBS buffer at pH 4.2. The reaction 
was stopped with 250 mM oxalic acid (Sigma-Aldrich) and measured at OD450nm in an 
ELISA reader (Bio-Rad, Veenendaal, the Netherlands). Data were analyzed using Microplate 
Manager software version 4 (Bio-Rad). Sensitivities of the ELISA were 10 ng/ml for IgM and 
5 ng/ml for IgG.
ELISPOT assay
To determine the number of IgM and IgG producing cells, we developed an ELISPOT assay. 
B cells were cultured at 104 cells per well in a 96-well round bottom plate (BD Falcon) 
with either 103 L-CD40L cells/well or anti-CD40 mAb + CpG in the presence of 100 ng/ml 
cyclosporin, 1 ng/ml tacrolimus, 50 ng/ml MPA or 1 ng/ml rapamycin. These concentrations 
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were chosen to yield sufficient numbers of cells for subsequent analysis. ELISPOT plates 
(Millipore, Amsterdam, the Netherlands) were prepared by coating with either goat anti-
IgM or anti-IgG (Jackson Immunoresearch) in PBS and blocked with 5% FCS/IMDM. At day 
6, cells were harvested, washed, counted and seeded in the ELISPOT plates at 6×103, 3×103 
and 1.5×103 cells/well in 5% FCS/IMDM. These fixed cell concentrations were used to 
eliminate the potential effect of the immunosuppressive drugs on cell numbers during the 
first culture. A more extensive dilution series of B cells cultured without immunosuppressive 
drugs was included for a standard dilution curve. After 6 h of incubation at 37°C, cells were 
lysed with water. Following washing, the plates were incubated with biotinylated anti-IgM 
or anti-IgG (both from Biosource) overnight at 4°C. Plates were washed and incubated 
with streptavidin-conjugated alkaline phosphatase (Sigma-Aldrich) for 1 h at RT followed 
by incubation of BCIP-NBT (Mabtech, Nacka Strand, Sweden) for 5 min. The reaction was 
stopped by rinsing with water. Plates were analyzed using a computer guided ELISPOT 
reader (Bioreader 3000, Bio-Sys GmbH, Karben, Germany). The cell number selected for 
analysis of drug effects was in the log phase of the standard dilution curve.
Apoptosis Assay
For determination of the percentage of apoptotic cells after culture, Propidium Iodide (PI) 
and Annexin-V-FITC (VPS Diagnostics, Hoeven, the Netherlands) were used following 
manufacturers’ descriptions. In brief, CD19+ cells were cultured at 5×105 cells per well 
in 24-well plates (Costar, Veenendaal, the Netherlands) with either 5×104 L-CD40L cells 
or anti-CD40 mAb + CpG, both in the presence of immunosuppressive drugs. After 3 
days, cells were harvested and resuspended at 3×105 cells/ml. Annexin-V-FITC and PI were 
added and incubated for 10 min on ice. Cells were acquired using a FACS Calibur (BD 
Biosciences) and analyzed using CellQuest Pro software (BD Biosciences).
Toxicity assay
To test whether the immunosuppressive drugs were toxic to B cells, a lactate dehydrogenase 
(LDH) activity assay (Roche Diagnostics GmbH, Mannheim, Germany) was performed 
according to the manufacturer’s instructions. Briefly, 2×105 B cells were cultured in 96-well 
round bottom plates in the presence of the immunosuppressive drugs in concentrations 
used in the proliferation assays. The culture was done in RPMI 1640 (Gibco) supplemented 
with 5% human serum (Sanquin Blood Supply, Leiden, the Netherlands) and 0.05 mM 
2-mercaptoethanol. After 16 h incubation, cells were spun and 100 µl of cell-free 
supernatants were incubated with 100 µl of the kit’s substrate for 30 min. The reaction 
was terminated with 1N HCl. Plates were read on the ELISA reader, and results were 
MMF and rapamycin directly inhibit B cells
39
2
expressed as OD490nm minus OD620nm.
Statistics
The paired T test was used for the analysis of the effects of single doses of immunosuppressive 
drugs on proliferation, immunoglobulin production and the number of immunoglobulin 
producing cells. Statistical level of significance was defined as P<0.05.
RESULTS
Effects of the different stimuli on purified B cells
We tested if CD40 ligation in combination with B cell activating cytokines (17) was 
sufficient for activating human B cells. In mice, B cell receptor signaling is not required 
when antigen specific T cell help is provided (18). Similarly, we observed that CD40 ligation 
using either anti-CD40 mAb or L-CD40L cells in combination with cytokines is sufficient 
to obtain proliferative, immunoglobulin producing B cells (Figure 1). As CpG was shown to 
have an important role in B cell activation (19, 20), we also developed a culture condition 
including the TLR9 ligand CpG ODN 2006 (Figure 1). B cells cultured with L-CD40L cells 
proliferated vigorously and produced large quantities of both IgM and IgG. Culturing with 
µ µ
Stimuli:
1. L-CD40L cells, IL-2, IL-10, IL21
2. anti-CD40 mAb, CpG, IL-2, IL-10, IL-21
3. anti-CD40 mAb, IL-2, IL-10, IL21
n=11 n=11
(a) (b)
Figure 1. Proliferation, IgM and IgG production induced in three culture conditions. (a) Purified B cells were cultured for 
7 days and 3H TdR was added for the last 18 h for proliferation assessment. (b) Supernatants collected at day 6 were 
tested for the presence of IgM and IgG with ELISA. CPM: counts per minute.
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anti-CD40 mAb + CpG resulted in intermediate levels of proliferation and immunoglobulin 
production. Stimulation with anti-CD40 mAb resulted in low B cell proliferation and 
immunoglobulin production. The latter stimulus was not used in some subsequent assays 
because of low cell yield. There was no correlation between the degree of responsiveness 





Figure 2. Immunosuppressive drugs are not toxic and have differential effects on the proliferation of B cells. (a) The 
LDH activity was measured in supernatants of B cells that were incubated with serial dilutions of immunosuppressive 
drugs. The effects of the highest concentrations of drugs are shown of a representative experiment (n=3). (b) Purified 
B cells were stimulated with L-CD40L cells in the presence of graded concentrations of immunosuppressive drugs. 
The percentage of proliferation relative to the addition of no immunosuppressive drugs is shown. *p<0.05; **p<0.01; 
***p<0.001 and ****p<0.0001. Horizontal bars indicate mean values. (c) Proliferation of anti-CD40 mAb + CpG 
stimulated B cells cultured with immunosuppressive drugs, legend as figure 2b. (d) Effect of immunosuppressive drugs 
on anti-CD40 mAb stimulated B cells, legend as figure 2b.
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Effects of immunosuppressive drugs on B cell proliferation
The immunosuppressive drugs were not toxic to B cells in the concentrations used, as 
tested by an LDH release assay (Figure 2a). Solvents of the immunosuppressive drugs did not 
affect B cells, warranting that effects observed are solely caused by the immunosuppressive 
drugs (data not shown). 
Tacrolimus in concentrations up to 1 ng/ml had minimal effects on the proliferation of B 
cells regardless of the stimulus (Figure 2b-d). It was previously shown that Staphylococcus 
aureus induced B cell proliferation was susceptible to high doses of tacrolimus (21). We 
therefore tested tacrolimus up to 16 ng/ml and found that high concentrations did not 
result in a stronger inhibition (data not shown). 
Cyclosporin had no effect on proliferation when B cells were cultured with L-CD40L 
cells (Figure 2b). However, we observed a moderate inhibition of proliferation with B cells 
stimulated with anti-CD40 mAb + CpG (Figure 2c). Cyclosporin strongly inhibited the 
proliferation of anti-CD40 stimulated B cells (Figure 2d). No effect of either tacrolimus 
or cyclosporin on proliferation was observed when the drugs were added 48 h after 
culture initiation (data not shown). This is in concordance with the mechanism of action of 
calcineurin inhibitors on T cells, which is early in activation (22). 
In contrast with the calcineurin inhibitors, both MPA and rapamycin were extremely 
potent inhibitors of B cell proliferation. MPA as well as rapamycin almost completely 
inhibited proliferation of B cells, regardless of the stimulus (Figure 2b-d). The inhibition 
was dose-dependent. Moreover, MPA or rapamycin were still effective when added 48 h 
after stimulation (data not shown).
MPA and Rapamycin induce apoptosis in B cells
A possible explanation for the inhibition of proliferation is the induction of apoptosis. 
To test this, B cells were cultured for 3 days with L-CD40L cells or anti-CD40 mAb + 
CpG in the presence of graded concentrations of immunosuppressive drugs after which 
B cell apoptosis was determined by Annexin-V and PI staining followed by FCM analysis 
(exemplified in Figure 3a). Tacrolimus and cyclosporin did not induce higher levels of 
apoptosis in the B cells when compared to controls. In contrast, addition of both MPA 
and rapamycin caused an increase of the percentage of apoptosis and this effect was dose 
dependent (Figure 3b).
Effects of immunosuppressive drugs on immunoglobulin production
Tacrolimus was marginally effective in inhibiting the production of both IgM and IgG 
with all culture conditions (Figure 4a-f). The degree of inhibition was dependent on the 
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anti-CD40 mAb + CpG stimulated B cells                 L-CD40L stimulated B cells
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Medium Tacrolimus 1.0 ng/ml Cyclosporin 100 ng/ml MPA 100 ng/ml Rapamycin 2.0 ng/ml(a)
(b)
strength of the B cell stimulation. Cyclosporin inhibited IgG production in all stimulatory 
conditions, and IgM in all except the most potent (L-CD40L) conditions (Figure 4a-f). 
Figure 3. Apoptosis induction by immunosuppressive drugs. B cells were stimulated with either anti-CD40 mAb + 
CpG or L-CD40L in the presence of two concentrations immunosuppressive drugs. After 3 days cells were stained with 
Annexin-V and PI and analyzed by flow cytometry. (a) Effect of immunosuppressive drugs on the percentage of apoptotic 
cells stimulated with anti-CD40 + CpG. Depicted are dot plots of B cells treated with the highest concentration immu-
nosuppressive drugs. The lower left quadrant are live cells, the lower right quadrant are early apoptotic cells, the upper 
right quadrant are late apoptotic cells and the upper left quadrant represents dead cells. (b) Percentage of apoptotic 
cells stimulated with anti-CD40 mAb + CpG (left panel) or L-CD40L (right panel) in the presence of two concentrations 
immunosuppressive drugs. Data from a representative experiment are shown.
Effects on immunoglobulin production of anti-CD40 mAb stimulated B cells were 
profound. Concurrent with the effects on proliferation, both tacrolimus and cyclosporin 
added 48 h after culture initiation failed to inhibit IgM as well as IgG production (Figure 5). 
In line with proliferation inhibition, both MPA and rapamycin were very potent in 
inhibiting immunoglobulin production. Addition of these immunosuppressive drugs led to 
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a virtually complete inhibition of IgM and IgG production in B cells cultured with any of the 
culture conditions (Figure 4a-f). These effects on immunoglobulin production were dose 
dependent. Addition of MPA and rapamycin 48 h after stimulation was equally effective in 
inhibiting IgM and IgG production compared to direct addition to the cultures (Figure 5).
Rapamycin decreases the number of immunoglobulin producing cells
To test whether the decrease in immunoglobulin production by the various 
immunosuppressive drugs was solely due to lower cell numbers caused by proliferation 
inhibition and/or induction of apoptosis, we developed an ELISPOT assay in which we 
enumerated the number of IgM and IgG producing cells. We normalized the effects on 
B cell division and apoptosis by adding fixed living cell numbers into ELISPOT plates, and 
therefore the effects of immunosuppressive drugs on the percentage of immunoglobulin 
producing cells reflected the effects within the live cell population only. 
Tacrolimus, cyclosporin and MPA did not decrease the number of immunoglobulin 
producing cells (data not shown and Figure 6). MPA marginally inhibited the number of IgG 
producing cells when B cells were stimulated with anti-CD40 mAb + CpG, but this was 
not dose-dependent. In contrast, rapamycin significantly and dose dependently decreased 
the number of IgM and, to a lesser extent, IgG producing B cells with either L-CD40L cells 
or anti-CD40 mAb + CpG stimulus (Figure 6).
DISCUSSION
The impact of humoral immunity on transplant outcome is increasingly recognized, as 
antibodies are associated with various types of rejection. The development of HLA 
antibodies was shown to precede all chronic rejections of kidney transplants (23). 
Moreover, post-transplant donor HLA-specific antibodies were described to have a strong 
predictive value for transplant outcome (24). Peritubular capillary (PTC) deposition of C4d 
was associated with circulating antibodies and both chronic and acute rejections (25, 26). 
This deposition was shown to be a predictor of inferior 12-month graft function (27). In 
as many as 60% of all patients with chronic rejection a positive PTC staining for C4d was 
observed (25).
A substantial number of in vitro studies have been performed on effects of immunosuppressive 
drugs on B cells with either tonsillar or peripheral blood B cells stimulated with a variety of 
agents (28-32). Diversity in study parameters makes comparison of results difficult. To our 






Figure 4. Effects of immunosuppressive drugs on immunoglobulin production. Supernatants from 6-day B cell cultures 
with immunosuppressive drugs were examined for the amount of IgM and IgG produced. (a-c) Percentage of IgM produc-
tion with graded concentrations immunosuppressive drugs relative to the addition of no immunosuppressive drugs for 
B cells stimulated with L-CD40L cells, anti-CD40 mAb + CpG and anti-CD40 mAb, respectively. *p<0.05; **p<0.01; 
***p<0.001 and ****p<0.0001, horizontal bars indicate mean values. (d-f ) Percentage of IgG production of L-CD40L 
cell, anti-CD40 mAb + CpG and anti-CD40 mAb stimulated B cells, respectively, treated with immunosuppressive drugs. 
Legend as figure 4a-c.
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drugs on purified B cells in a well-defined experimental system. 
We made use of three methods to stimulate B cells into proliferating, immunoglobulin 
producing cells. In this manner, we were able to investigate whether the effect of 
immunosuppressive drugs depended on the strength and type of stimulus. These stimuli 
are polyclonal and can therefore not be extrapolated to antigen-specific humoral immune 
responses.
Calcineurin inhibitors are included in most immunosuppressive regimens, often combined 
with steroids. As a major proportion of chronic rejections in patients receiving Cyclosporin-
based immunosuppression appears to be antibody-mediated, this drug clearly is not able to 
prevent humoral rejection (25). We tested the effect of both tacrolimus and cyclosporin 
on B cell responses. We have taken the binding of calcineurin inhibitors to erythrocytes 
into consideration for selecting drug concentrations to be tested. Our in vitro data support 
cyclosporin’s relative ineffectiveness in directly inhibiting B cell responses. Likewise, 
tacrolimus had only marginal effects on B cell parameters. While multiple reports showed 
that in case of acute or chronic humoral rejection rescue therapy with tacrolimus and 
MMF was effective in reverting the rejection episodes (33-35), our data suggest that MMF 
Figure 5. Calcineurin inhibitors are not effective in inhibiting IgM and IgG production when added 48 h after the start 
of the stimulation whereas MPA and rapamycin are still effective. Shown are effects of the highest concentrations of 
immunosuppressive drugs added to anti-CD40 mAb + CpG stimulated B cells. The percentage of inhibition relative to no 
addition of immunosuppressive drugs is depicted.
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is likely to be the main drug responsible for the effect. In a multi-center study, MMF in 
combination with cyclosporin resulted in significantly lower frequencies of HLA antibodies 
as compared with azathioprine and cyclosporin treatment (36). Moreover, MMF was 
described to be very effective in inhibiting primary antigen-specific antibody responses in 
renal transplant patients (37). 
n=6
L-CD40L cells, IL-2, IL10, IL21
anti-CD40 mAb, CpG, IL-2, IL-10, IL-21
(a)
(b)
Figure 6. Rapamycin diminishes the number of immunoglobulin producing cells, whereas MPA does not. Open bars 
represent B cells stimulated with L-CD40L cells and filled bars represent B cells stimulated with anti-CD40 mAb + CpG. 
(a) MPA did not dose-dependently inhibit the percentage of both IgM and IgG producing cells. (b) Rapamycin dose-
dependently inhibited both the percentage of IgM and IgG producing cells. The effect on IgM producing cells was more 
profound than on IgG producing cells. *p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001.
In our experiments, MPA was extremely potent in inhibiting both proliferation and 
immunoglobulin production. Moreover, these effects persisted when MPA was added to 
already activated B cells, implying that an ongoing B cell response may be dampened by 
MPA, while calcineurin inhibitors are ineffective. MPA levels used are lower than levels that 
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are usually achieved physiologically. In the experiments describing proliferation and total 
IgG and IgM levels in the supernatant of B cell cultures, we found in preliminary experiments 
already a complete inhibition when using these suboptimal MPA concentrations. Any higher 
dose would not result in a dose-dependent effect and would therefore raise the question 
whether the effect would be biologically relevant. In subsequent experiments such as 
the apoptosis and ELISPOT tests, we needed sufficient numbers of cells to analyze. Since 
MPA profoundly induced apoptosis already at 100 ng/ml, we were not able to perform 
these tests with higher concentrations than 50 ng/ml. Therefore, the effects observed 
might therefore even be an underestimation of the suppression of B cell function in vivo. 
Furthermore, an effect of MPA, in clinically relevant concentrations, on the number of 
immunoglobulin producing cells cannot be excluded.
Rapamycin is generally not included in maintenance immunosuppressive protocols from 
the day of transplantation onwards because it causes delayed graft function (38), increases 
surgical complications and impairs wound healing (39). However, rapamycin, like MMF, 
was described to be extremely potent in inhibiting humoral responses. For example, 
in vivo data comparing cyclosporin in combination with either azathioprine, MMF or 
rapamycin on the formation of antibodies against equine antithymocyte globulin after renal 
transplantation show that both MMF and rapamycin are capable of reducing anti-equine 
antibody formation (40). In our in vitro experiments rapamycin was the most effective drug 
tested, as it inhibited not only B cell proliferation and immunoglobulin production, but also 
inhibited the number of immunoglobulin producing cells. None of the other drugs tested 
were capable of decreasing the number of immunoglobulin producing cells.
An important effector mechanism of immunosuppressive drugs is apoptosis induction. 
We found that MPA and rapamycin induced B cell apoptosis. Since rapamycin induced 
apoptosis in dendritic cells as well, it is likely that this is a general effect of rapamycin 
(41). Since we stimulated the B cells polyclonally, we were not able to identify specific 
populations of B cells susceptible or resistant to apoptosis induction.
To get more insight in the possible mechanism of action on B cells, we performed 
cytokine production analyses on supernatants of B cells cultured in the presence of 
immunosuppressive drugs, but no correlations with the outcome of the proliferation and 
immunoglobulin data were found (data not shown). The antigen presenting function of B 
cells may play an important role in the process of allograft rejection (42). We therefore 
performed phenotypic analysis of B cells stimulated with anti-CD40 mAb and CpG treated 
with immunosuppressive drugs, but observed no alterations in the expression levels of 
HLA-DR, CD80 and CD86 (data not shown), suggesting that antigen presentation is not 
altered. However, studies using antigen specific interactions between B cells and T cells 
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are needed to address the influence of immunosuppression on the APC function of B cells 
in more detail.
Besides the effects of rapamycin described here, there are additional effects that would 
argue in favor of the use of rapamycin. Data on favorable effects of rapamycin on regulatory 
T cell subsets are emerging. A selective survival of both CD4+CD25+Foxp3+ as well as 
CD103+CD8+ regulatory T cells was recently described (43, 44). These effects are not 
observed for other immunosuppressive drugs such as cyclosporin (45, 46). Furthermore, 
rapamycin has been described to inhibit angiogenesis and might therefore be anti-
tumorigenic (47). 
In the present study, the effects of immunosuppressive drugs on T cell help are not taken 
into account. Whereas the prime target of calcineurin inhibitors is the T cell, the effect 
of calcineurin inhibitors might be underestimated. However, baseline calcineurin inhibitor 
therapy appears not to be very effective to prevent humoral rejection (25). To get more 
insight into this, studies on the in vitro effects on T cell dependent B cell responses are 
currently performed in our laboratory.
Many clinical studies are currently focused on drug tapering and withdrawal. Tapering 
or sparing of calcineurin inhibitors is widely performed to minimize their side effects 
(reviewed in (48)). Our data suggest that tapering of calcineurin inhibitors will most likely 
not increase the risk of humoral rejection. 
Taken together, evaluation of highly purified, polyclonally stimulated B cells shows that MPA 
and rapamycin were superior in inhibiting B cell functionality in vitro, which underscores 
the clinical usefulness of these drugs for respectively prevention and treatment of humoral 
rejection. However, to predict accurately which immunosuppressive regimen will be optimal 
for treating humoral rejections, in vitro studies with combinations of immunosuppressive 
drugs are essential. Studies of this kind are currently underway in our laboratory, and are 
intended to define a combination regimen that can be preferentially used to treat humoral 
rejection.
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Calcineurin inhibitors affect B cell antibody 
responses indirectly by interfering with 
T cell help
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In general, humoral immune responses depend critically on T cell help. In transplantation, 
prevention or treatment of humoral rejection therefore requires drugs that ideally inhibit 
both B cell and T helper cell activity. Here, we studied the effects of commonly used im-
munosuppressive drugs (tacrolimus, cyclosporin, MPA and rapamycin) on T cell helper 
activity and on T cell dependent B cell responses. 
T cells were polyclonally activated in the presence of immunosuppressive drugs in order 
to analyse the effect of these drugs on T cell proliferation, costimulatory ligand expression 
and cytokines. The impact of immunosuppressive drugs on T cell dependent immuno-
globulin production by B cells was addressed in T – B cell cocultures.
All drugs affected T cell proliferation and attenuated T cell costimulatory ligand (CD154 
and CD278) expression when T cells were polyclonally activated. Tacrolimus, cyclosporin 
and rapamycin also attenuated B cell stimulatory cytokine mRNA levels in T cells. As a 
consequence, a decrease in immunoglobulin levels was observed in autologous T – B cell 
cocultures, where T cell help is essential for immunoglobulin production. In contrast, 
when preactivated T cells were used to stimulate autologous B cells, calcineurin failed to 
inhibit B cell immunoglobulin production, whereas MPA and rapamycin did show inhibition.
From these studies it is evident that calcineurin inhibitors affect the humoral immune re-
sponse by interfering with T helper signals, but not by targeting B cells directly. Our stud-
ies furthermore support the necessity of intervening in T cell helper function to attenuate 
humoral responses. 
 




Despite excellent one-year graft survival rates, graft rejection remains an issue in solid or-
gan transplantation. Although hyperacute rejection is avoided by pre-transplant serological 
crossmatching (1) and acute rejection is treatable with current immunosuppressive drugs, 
rejection pathology still occurs and has shifted towards a later stage after transplantation. 
Typically, the cause of chronic organ failure is multi-factorial though, involving both immu-
nologic and non-immunologic damage, termed chronic allograft vasculopathy (2). In recent 
years, the role of humoral immunity in the development of chronic rejection has become 
increasingly apparent, as anti-HLA antibodies are frequently detected prior to chronic 
kidney rejection (3). Staining for the complement split product C4d also revealed a strong 
correlation between chronic rejection and humoral immunity (4).
Medication for treatment of acute rejection is well defined. Steroids are administered to 
patients undergoing rejection which, in case of steroid resistance, are followed by anti-
thymocyte globulin (ATG) (5). In contrast, therapy for chronic (humoral) rejection is less 
well defined. Besides standard immunosuppressive drugs, intervention strategies include 
administration of ATG, high dose IVIg, Rituximab and plasmapheresis (6-10).
Although terminology implies a clear division, cellular and humoral rejection are inter-
twined. B cells act as potent antigen presenting cells capable of activating T cells, thereby 
possibly enhancing cellular rejection (11). Conversely, most B cells will only get properly 
activated when T cell help is provided (12). Furthermore, T cells are needed for B cell 
class-switching and production of potentially harmful IgG antibodies (13). Besides cognate 
interaction via antigen, the T cell mediated activation of B cells takes place through CD40L 
(CD154) – CD40 and, inducible costimulator (ICOS; CD278) – ICOSL interaction, as well 
as through cytokine production and consumption. Therefore, drugs that preferentially act 
on T cells, such as calcineurin inhibitors, are likely to affect humoral immune responses.
Previously, we have reported that the function of highly purified B cells, upon CD40 driven 
activation, was inhibited by mycophenolic acid (MPA) and rapamycin, but not by calcineurin 
inhibitors tacrolimus and cyclosporin, especially when B cells were strongly stimulated 
(14). In the present study, we have investigated the effect of these immunosuppressive 
drugs on T cell help and addressed the question whether calcineurin inhibitor-induced 
inhibition of T cell help is sufficient for the prevention of immunoglobulin production by B 





Blood was obtained from healthy blood bank donors after informed consent. Periph-
eral blood mononuclear cells (PBMC) were isolated by Ficoll Hypaque density gradient 
centrifugation. Untouched CD4+ T cells were obtained from PBMC by magnetic separa-
tion using the CD4+ T cell isolation kit II (Miltenyi, Bergisch-Gladbach, Germany) and 
MS columns (Miltenyi). After separation, flow cytometric analysis (FCM) revealed >80% 
purity. B cells were immunomagnetically isolated from PBMC by positive selection using 
Dynabeads CD19 pan B and Detach-a-Bead CD19 (Invitrogen, Leek, the Netherlands), 
typically yielding >98% pure B cells, as assessed by FCM. Cells were cultured in Iscove’s 
modified Dulbecco’s medium (IMDM) (Gibco, Paisley, UK) supplemented with 10% fetal 
calf serum (FCS) (Gibco), 0.05 mM 2-mercaptoethanol (Sigma-Aldrich, Zwijndrecht, the 
Netherlands) and insulin-tranferrin-selenium (ITS) (insulin 5 µg/ml, transferrin 5 µg/ml and 
selenium 5 ng/ml, Sigma-Aldrich).
Immunosuppressive drugs
Tacrolimus (Prograf, Astellas, Leiderdorp, the Netherlands, diluted in ethanol) and cyclo-
sporin (Sandimmune obtained from Novartis, Arnhem, the Netherlands) were used at final 
concentration ranges of 0-1 ng/ml and 0-100 ng/ml, respectively, based on plasma levels 
measured at 6 months post-transplantation (15-17). Calcineurin inhibitor concentrations 
reported for whole blood are considerably higher, but it should be noted that in vivo a sub-
stantial fraction of these drugs is bound to erythrocytes (18, 19), which are not present in 
our cultures. Mycophenolic acid (MPA, Sigma-Aldrich), the active metabolite of mycophe-
nolate mofetil (MMF), was dissolved in ethanol and used in concentrations up to 100 ng/
ml, which is approximately 10-fold lower than used in patients. This concentration range 
was chosen because maximal effects were already observed using 100 ng/ml. Rapamycin 
(Calbiochem, La Jolla, CA, USA) was dissolved in methanol and used in concentrations up 
to 8 ng/ml, which is within the clinical range. Solutions of immunosuppressive drugs were 
diluted in culture medium.
CFSE assay
T cells (105) were carboxyfluorescein succinimidyl ester (CFSE from Invitrogen, 10 µM) 
labelled for 10 min at 37°C and cultured with 5 µg/ml anti-CD28 mAb (CLB-CD28/1, 
Sanquin, Amsterdam, the Netherlands) in 24-well plates (Costar, Veenendaal, the Neth-
erlands) that had been coated with 5 µg/ml anti-CD3 mAb (UCHT1, BD Biosciences, 
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Breda, the Netherlands). Cells were harvested at day 3 and stained with CD4-PE (BD 
Biosciences) and Sytox Red dead cell stain (Invitrogen, Leek, the Netherlands) for dead cell 
exclusion. The proliferation index was calculated as follows (adapted from (20)): 
total events / ∑(events in peak[n]/2(n-1))
Peak 1 represents the undivided peak. Data are expressed as percentage of the prolifera-
tion index relative to no addition of immunosuppressive drugs. To calculate this percent-
age, data were transformed such that a proliferation index of zero represents no division.
Cytokine mRNA detection
T cells (5×105) were stimulated for 8 h with anti-CD3 mAb / anti-CD28 as described 
above in the presence or absence of immunosuppressive drugs. Cells were harvested and 
preserved in RNAlater solution (Qiagen, Chatsworth, CA, USA). RNA was extracted 
using the RNeasy® mini kit (Qiagen) following the manufacturer’s instructions. RNA was 
treated with DNase (Qiagen) on the spin columns and RNA quantity was assessed with a 
spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). All samples showed 
A260/A280 ratios between 1.9 and 2.1. cDNA was synthesized by incubating 12.8 µl RNA 
solution with 7.2 µl cDNA mix containing 2’-deoxynucleosides 5’ triphosphate (dNTPs) 
(final concentration of 0.5 mM), 2 U reverse transcriptase-avian myeloblastosis virus (RT-
AMV), 20 U rRNase inhibitor, 100 ng oligo-dT primers, 500 ng of random primers, and 1x 
reverse transcriptase buffer (all from Promega, Leiden, the Netherlands).
Primer sets (Table 1) for quantitative polymerase chain reaction (Q-PCR) were selected 
using Beacon Designer Software (version 7.02, Premier Biosoft International, Palo Alto, 
CA, USA) and were obtained from Eurogentec (Liège, Belgium). PCR mixes contained 1 
µM of forward and reverse primers, 3 mM MgCl2, and 1× iQ SYBR Green supermix (Bio-
Rad, Veenendaal, the Netherlands). PCR was performed using an iCycler MyiQ (Bio-Rad). 
The PCR program consisted of one cycle of 10 min at 95°C, 40 cycles of 15 sec at 95°C 
and 1 min at 60°C, and was finalized with a melting curve analysis. Reactions were carried 
out in optical 96-well plates (Bio-Rad) covered with Microseal ‘B’ Film (Bio-Rad). The 
mean signal of the stably expressed reference genes 18S rRNA, GAPDH, β-actin, HPRT, 





T cells (5×105) were stimulated for 24 h with anti-CD3 mAb / anti-CD28 mAb as described 
above in the presence of graded concentrations of immunosuppressive drugs. Cells were 
harvested and labelled with the following mAb conjugates: CD4-PerCP, CD25-PE, CD154-
PE, CD278-PE and CD69-FITC (all from BD Biosciences). Dead cells were excluded using 
Sytox Red. Cells were acquired using a FACS Calibur and analyzed using CellQuest Pro 
software (BD Biosciences).
Table 1. Sequences for primers used in quantitative polymerase chain reaction (Q-PCR).
Transcript Forward primer Reverse primer Amplicon
IFN-γ AGCTCTGCATCGTTTTGGGTT GTTCCATTATCCGCTACATCTGAA 118 bp
IL-2 AGGATGCTCACATTTAAGTTTTAC GAGGTTTGAGTTCTTCTTCTAGACACTGA 85 bp
IL-4 GTCTCACCTCCCAACTGCTT GTTACGGTCAACTCGGTGCA 157 bp
IL-5 AGCCAATGAGACTCTGAGGATTC GACTCTCCAGTGTGCCTATTCC 95 bp
IL-10 GCGCTGTCATCGATTTCTTCC GTAGATGCCTTTCTCTTGGAGCTTA 94 bp
IL-13 TCCTCTCCTGTTGGCACTG AGCGGAGCCTTCTGGTTC 165 bp
IL-21 AAACCACCTTCCACAAATGC AGAGGACAGATGCTGATGAATC 147 bp
18S rRNA AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC 68 bp
GAPDH ACCCACTCCTCCACCTTTGAC TCCACCACCCTGTTGCTGTAG 110 bp
HPRT-1 AGATGGTCAAGGTCGCAAGC TCAAGGGCATATCCTACAACAAAC 115 bp
HMBS GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC 64 bp
RPL13a CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA 126 bp
β-actin ACCACACCTTCTACAATGAG TAGCACAGCCTGGATAGC 161 bp
bp: base pairs.
T and B cell cocultures
T cells (1.5×103) were stimulated for 9 days with anti-CD3 mAb / anti-CD28 mAb as de-
scribed above in the presence of autologous B cells (1.5×105) with 2.5 µg/ml of the Toll-like 
receptor ligand cytosine-guanine dinucleotide oligodeoxynucleotide (CpG ODN) 2006 
(Hycult Biotechnology, Uden, the Netherlands). A T – B cell ratio of 1:100 was chosen 
because of strong proliferation of T cells after polyclonal stimulation, resulting in a 1:1 ratio 
after 9 days of culture (data not shown).
For some experiments, T cells (5×105) were prestimulated with anti-CD3 mAb / anti-
CD28 mAb and 100 U/ml IL-2 (EuroCetus, Amsterdam, the Netherlands) for 2 days. After 
washing, 5×104 T cells were cocultured with 5×104 B cells with the addition of CpG for 6 
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days instead of 9 days, since T cell were already activated in the preculture. Furthermore, 
cells were cultured in a 1:1 ratio, since cocultures were performed without continued T 
cell stimulation, resulting in only minor T cell proliferation.
Immunoglobulin levels
Supernatants were tested for IgM and IgG levels with a standard sandwich ELISA. Plates 
(Greiner, Alphen a/d Rijn, the Netherlands) were coated overnight with a goat anti-IgG or 
anti-IgM (Jackson Immunoresearch, Westgrove, PA, USA) diluted in 10 mM Tris pH 9.0, 
and then blocked with 2% bovine serum albumin (BSA, Sigma-Aldrich) in 0.025% Tween-20 
(Sigma-Aldrich) in PBS (PBS-T). Fifty microliters of supernatants or standard human serum 
(Sanquin, Amsterdam, the Netherlands) in a serial dilution were incubated for 60 min 
at 37°C. After washing with PBS-T, biotin labelled goat anti-IgM or anti-IgG (Biosource, 
Camarillo, CA, USA) diluted in 1% BSA/PBS-T was incubated for 60 min at 37°C. After 
extensive washing, streptavidin horseradish peroxidase (Pierce, Rockford, IL, USA), di-
luted in 1% BSA/PBS-T was added and incubated for 60 min at 37°C. A color reaction was 
obtained with 4.6 mM 2,2’-azine-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS, Sigma-
Aldrich) in a citric acid/PBS buffer at pH 4.2. The reaction was stopped with 250 mM oxalic 
acid (Sigma-Aldrich) and measured at OD450nm in an ELISA reader (Bio-Rad). Data were 
analyzed using the Microplate Manager software version 4 (Bio-Rad).
Statistics
The one-sample T test was used for the analysis of immunoglobulin levels induced by dif-
ferent conditions within one donor. The paired T test was used for the analysis of single 
doses of immunosuppressive drugs. Statistical level of significance was defined as P<0.05.
RESULTS
Effects of immunosuppressive drugs on T cell activation and proliferation
T cell activation with anti-CD3 mAb / anti-CD28 mAb led to a substantial increase of 
CD25+ and CD69+ cells (Figure 1a). None of the immunosuppressive drugs altered the 
percentage of CD25+ cells, whereas only cyclosporin slightly inhibited the percentage of 
CD69+ cells (Figure 1b). Additionally, polyclonal T cell activation resulted in a strong prolif-
erative response, as measured by CFSE (Figure 1c, upper left panel). Since immunosuppres-





















Figure 1. Immunosuppressive drugs did not alter T cell activation but did inhibit T cell proliferation. (a) T cell activation 
with anti-CD3 mAb / anti-CD28 mAb for 24 h resulted in upregulation of CD25 and CD69. (b) None of the immunosup-
pressive drugs affected CD25 levels, whereas cyclosporin inhibited the expression of CD69. Drug concentrations were 1.0 
ng/ml tacrolimus, 100 ng/ml cyclosporin, 100 ng/ml MPA and 8.0 ng/ml rapamycin. Data are expressed as percentage 
of cells expressing CD25 or CD69 as compared to medium controls (dotted lines), n=4. (c) CFSE labelled T cells were 
activated with anti-CD3 mAb / anti-CD28 mAb for 3 days in the presence of immunosuppressive drugs. Data from a 
representative experiment are shown. Similar results were obtained in three independent experiments. (d) Percentage 
inhibition of the T cell proliferation index by immunosuppressive drugs compared to medium controls (dotted lines) are 
depicted, n=3. Drugs concentrations were: 0.3 ng/ml tacrolimus, 50 ng/ml cyclosporin, 100 ng/ml MPA and 4 ng/ml 
rapamycin. *P<0.05 and **P<0.01.
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resulted in low cell yields, insufficient for analysis. Therefore, we used suboptimal drug 
concentrations to address the effect of immunosuppressive drugs on T cell proliferation 
(Figure 1c). These relatively low, but clinically relevant, drug concentrations caused strong 
inhibition of the T cell proliferation index (Figure 1d).
Effect of immunosuppressive drugs on T cell helper function
Next, we investigated the effect of immunosuppressive drugs on T cell helper signals, 
by addressing costimulatory ligand expression and helper cytokines. Polyclonal T cell ac-
tivation led to increased numbers of CD154+ (CD40L) cells and, to a lesser extent, of 
CD278+ (ICOS) cells (Figure 2a). All immunosuppressive drugs attenuated the percentage 
of CD154+ cells to a similar extent, although cyclosporin inhibition did not reach statisti-
cal significance. The effects on CD278 were more profound. Cyclosporin was superior in 
inhibiting the percentage of CD278+ cells, as compared to tacrolimus, MPA and rapamycin 
(Figure 2b). 
We determined effects of immunosuppressive drugs on cytokines by their mRNA levels 
at 8 h post stimulation, rather than by their presence in culture supernatants to avoid 
confounding effects due to proliferation and cytokine consumption. Polyclonal T cell acti-
vation led to increased IFN-γ, IL-2, IL-4, IL-5 and IL-13 mRNA levels, whereas IL-10 mRNA 
remained stable and IL-21 mRNA was undetectable (data not shown). Tacrolimus inhibited 
all cytokines tested, although IL-5 inhibition did not reach statistical significance (Figure 
2c). Likewise, cyclosporin inhibited all cytokines tested, although not reaching statistical 
significance for IL-4, IL-5 and IL-10. MPA did not inhibit any of the cytokines tested al-
though the effect of MPA on cytokine mRNA expression varied highly between subjects. 
Rapamycin inhibited all cytokines tested except IL-13, but not to the same extent as the 
calcineurin inhibitors.
All immunosuppressive drugs affect T cell dependent B cell activation
To test the effects of immunosuppressive drugs on T cell dependent B cell activation, we 
developed a culture system in which B cells were activated in a T cell dependent manner, 
using polyclonal T cell activation in the presence of autologous B cells. In this test system 
T cells were necessary for B cell activation, since cultures of purified B cells alone with 
anti-CD3 mAb / anti-CD28 mAb and CpG resulted in low IgM and IgG levels, whereas high 
levels of IgM and IgG were produced in the presence of autologous T cells (Figure 3a). In 
these T – B cell cocultures, CpG was added to increase immunoglobulin production (21), 
however, CpG alone did not induce immunoglobulin production (data not shown). B cell 
activation was T cell contact dependent, since co-cultures of B cells with pre-stimulated T 
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Figure 2. Effect of immunosuppressive drugs on T cell stimulatory signals. (a) T cell stimulation with anti-CD3 mAb / 
anti-CD28 mAb for 24 h resulted in upregulation of CD154 and CD278. (b) All immunosuppressive drugs inhibited the 
expression of CD154 and CD278. Drug concentrations were 1.0 ng/ml tacrolimus, 100 ng/ml cyclosporin, 100 ng/ml 
MPA and 8.0 ng/ml rapamycin. Data are expressed as percentage of cells expressing CD154 or CD278 as compared to 
medium controls (dotted lines), n=4. (c) Immunosuppressive drugs inhibit the mRNA levels of B cell stimulatory cytokines 
produced by T cells to various extents. Data are expressed as percentage of cytokine mRNA inhibition compared to 
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cells in transwell plates resulted in low immunoglobulin production, whereas co-cultures 
performed in standard 24-well plates resulted in high IgM and IgG production (Figure 3b). 
To address the effects of immunosuppressive drugs on T cell dependent B cell cultures, 
freshly isolated T and B cells were cocultured with immunosuppressive drugs for 9 days 
in the presence of polyclonal T cell stimulation, after which supernatants were tested 
for immunoglobulin levels. As expected from their direct effects on B cells, MPA and 
rapamycin profoundly inhibited immunoglobulin levels in T cell dependent B cell cultures. 
Interestingly, tacrolimus and cyclosporin were equally potent in inhibiting T cell dependent 
immunoglobulin production as compared to MPA and rapamycin, indicating that inhibition 
of T cell help by calcineurin inhibitors is sufficient to prevent immunoglobulin production 
(Figure 4a and 4b). 
(a) (b)
Figure 3. T cells were necessary for B cell activation in a cell-cell contact dependent fashion. (a) B cells were cultured 
in anti-CD3 mAb coated wells with soluble anti-CD28 mAb in the absence or presence of autologous T cells. After 9 days 
supernatants were harvested for immunoglobulin assessment. (b) Co-cultures of B cells and pre-stimulated T cells were 
performed in either regular or transwell plates (B cells in lower compartment). Supernatants were harvested at day 6 for 
detection of immunoglobulins. **P<0.01 and ****P<0.0001.
Tacrolimus and cyclosporin fail to inhibit B cells directly
To corroborate that the calcineurin inhibitor-induced inhibition of immunoglobulin pro-
duction was due to the inhibition of T cell help, we developed a modification of the culture 
system described above in which T cells were already activated prior to coculture with 
autologous B cells. MPA and rapamycin almost completely inhibited immunoglobulin levels, 
ensuring that the B cells in this culture system were susceptible to inhibition by immu-
nosuppressive drugs (Figure 4c and 4d). In contrast, tacrolimus and cyclosporin failed to 
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Figure 4. All immunosuppressive drugs were capable of inhibiting immunoglobulin production when B cells are cultured 
with non pre-activated T cells, but calcineurin inhibitors failed to inhibit immunoglobulins levels when pre-activated T 
cells were used to stimulate B cells.  B cells were cultured with fresh, autologous T cells and anti-CD3 mAb / anti-CD28 
mAb with CpG in the presence of graded concentrations of immunosuppressive drugs for 9 days, whereupon superna-
tants were tested for IgM (a) and IgG levels (b). B cells were cultured with immunosuppressive drugs for 6 days with 
CpG in the presence of pre-stimulated T cells. Depicted are the percentages of IgM (c) and IgG (d) levels compared 




inhibit IgM production (Figure 4c), whereas cyclosporin marginally inhibited IgG levels (Fig-
ure 4d). Thus, the inhibition of B cell responses by calcineurin inhibitors that was shown in 
Figure 4a and 4b appears solely due to inhibition of T cell help. 




Chronic damage to transplanted organs can be caused by a variety of mechanisms, and 
in some of these, the binding of anti-HLA antibodies to the endothelium of the graft is 
implicated (3). For effective prevention and treatment of humoral rejection, immunosup-
pressive drugs should preferably affect the function of B cells as well as helper T cells, since 
T cell help by ligand interactions and cytokines activates B cells (12). Inhibition of T cell 
proliferation by calcineurin inhibitors and suppression of the transcription of the IL-2 gene, 
amongst others, is well known (22). Furthermore, calcineurin inhibitors attenuate T cell 
dependent Pokeweed Mitogen activation of B cells (23, 24). However, from these studies 
it is unclear whether the inhibition is due to inhibition of T cell help. 
We have previously shown that calcineurin inhibitors are not efficient in directly inhibiting 
B cells, in cultures of purified B cells, activated in the absence of T cells (14). These data 
raised the question whether calcineurin inhibitors inhibit humoral immune responses by 
the inhibition of T cell help. We therefore set out to determine whether, by inhibition of 
T cell help, calcineurin inhibitors were capable of inhibiting B cell immunoglobulin produc-
tion. Therefore, we developed a culture system in which B cells were activated in a T cell 
dependent fashion. Furthermore, we examined whether inhibition of T cell help was suf-
ficient to completely abrogate immunoglobulin production.
The number of T cells available to provide help towards B cells may be reduced by inhibi-
tion of proliferation, or induction of apoptosis. We showed that, although T cells did get 
highly activated, all immunosuppressive drugs tested were capable of inhibiting prolifera-
tion. As expected, MPA and rapamycin, well known for their anti-proliferative effect (25, 
26), were more potent in inhibition of T cell proliferation than the calcineurin inhibitors. 
Nonetheless, calcineurin inhibitors did inhibit T cell proliferation, which, at least partly, 
resulted in insufficient generation of activated T cells. None of the immunosuppressive 
drugs induced apoptosis in polyclonally activated T cells (data not shown).
The level of costimulation and cytokines mainly determines the strength of T cell help to-
wards B cells. Thus a possible mechanism of drug-induced suppression of T cell dependent 
humoral immune responses is the reduction of B cell stimulatory signals, either as ligand 
interaction or as soluble mediators. All immunosuppressive drugs decreased the number 
of cells expressing the costimulatory ligands CD40L and ICOS, reducing the ability of T 
cells to activate B cells. This is reminiscent of patients with defective CD40L, who suf-
fer from hyper-IgM syndrome (27) and patients with a homozygous deletion of the ICOS 
gene, who are severely antibody deficient (28). As expected, calcineurin inhibitors, but 
also rapamycin profoundly inhibited T cell IL-2 mRNA levels, which in turn can contribute 
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to the failure of B cell responses (29). Additionally, calcineurin inhibitors and rapamycin 
inhibited several other B cell differentiation cytokines, thereby abrogating B cell signals 
necessary for activation and class switching.
We performed T cell dependent B cells cultures to investigate whether the inhibition of T 
cell help by calcineurin inhibitors was of sufficient magnitude to cause downstream inhibi-
tion of B cell activation. Activation of T cells by immobilized anti-CD3 mAb eliminated 
the need for an antigen specific culture system to obtain immunoglobulin producing B 
cells (30). In the cocultures that we employed here, B cell activation was achieved via T 
cell activation and was cell contact dependent. In contrast to our previous findings in T 
cell free B cell cultures (14), tacrolimus and cyclosporin almost completely inhibited T cell 
dependent immunoglobulin production. The magnitude of inhibition was comparable to 
that caused by MPA and rapamycin, indicating that by inhibition T cell help, activation of B 
cells can be prevented.
It has previously been published that calcineurin inhibitors are incapable of inhibiting al-
ready activated T cells (31-33). This is in line with our current observations in cocultures of 
B cells with preactivated T cells, where tacrolimus and cyclosporin failed to inhibit immu-
noglobulin production. In contrast, MPA and rapamycin, which are able to inhibit activated 
T cells (26, 33) as well as to directly inhibit B cells (14), completely abrogated immuno-
globulin production. The marginal inhibition of IgG levels by cyclosporin suggests minor 
inhibition of B cells directly, which however, is far less potent than its effect on T cell help.
Taken together, our data show that calcineurin inhibitors can only prevent humoral re-
sponses by inhibiting T cell help. Consequently, these data stress the importance of target-
ing the T cell compartment to affect humoral immune responses.
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no direct effect on B cell proliferation and 
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Intravenous immunoglobulin (IVIg) is used for treatment of a variety of immunological 
disorders and in transplantation. As one of its applications in transplantation is the reduction 
of donor specific antibodies in the circulation, we examined the direct effect of IVIg on 
essential parameters of human B cell responses in vitro. Purified human B cells, human 
B cell hybridomas and T cells were cultured in the presence of graded concentrations 
of IVIg to test its effect on their proliferative capacity. To address the effect of IVIg on 
immunoglobulin production, we designed a novel technique making use of quantitative 
PCR to assess IgM and IgG levels. IVIg failed to inhibit proliferation of human B cells and 
human B cell hybridomas. In contrast, when IVIg was added to T cell cultures, a dose-
dependent reduction of the proliferative capacity was observed. IVIg did not to affect the 
levels of IgM and IgG mRNA of activated B cells. Our data show that IVIg is not capable 
of directly inhibiting key B cell responses. Direct B cell inhibition by IVIg seems therefore 
unlikely, implying that alteration in humoral immunity by IVIg is due to indirect effects on 
T cells and/or interactions with circulating antibodies and complement factors.
 




Intravenous immunoglobulin (IVIg) is a preparation of pooled human plasma prepared 
from over a thousand donors and was originally used as a substitution therapy for patients 
with immunodeficiencies (1). IVIg is increasingly used as treatment for autoimmune 
and systemic inflammatory diseases, and in the field of solid organ- and bone marrow 
transplantation. In organ transplantation settings, IVIg is used, among other treatments, 
to reduce plasma HLA antibody levels prior to transplantation (2-4) and in attempts to 
reverse acute humoral rejection (5).
The present study focuses on the effect of IVIg on humoral immunity. Several mechanisms 
have been proposed for its mode of action. Firstly, anti-idiotypic antibodies in IVIg may 
interfere in the reaction of HLA-specific antibodies with their targets on HLA mismatched 
organs, thereby preventing humoral rejection (6). Secondly, IVIg may bind through the Fc 
portion of IgG to the inhibitory FcγRIIb expressed on a variety of blood cells, including B 
cells, leading to the reduction of proliferation and apoptosis induction (7). Thirdly, IVIg may 
inhibit complement, and thereby modulate the effector function of antibodies (8). Fourthly, 
changes in monocyte Fc receptor functions can inhibit antibody-mediated immune damage 
(9). Lastly, clearance of pathogenic antibodies may be accelerated by saturation of the FcRn 
receptor (10).
We used a robust culture system, devoid of auxiliary cells, for stimulating purified human 
B cells, as well as autonomously proliferating human B cell hybridomas to study the direct 
effect of IVIg on B cell proliferation and immunoglobulin production. The latter was 
assessed by a novel, PCR based, technique for quantifying immunoglobulin production.
MATERIALS AND METHODS
Cells
Blood was collected from healthy blood bank donors with informed consent under 
guidelines issued by the Medical Ethics Committee of the Leiden University Medical Center 
(Leiden, the Netherlands). Peripheral blood mononuclear cells (PBMC) were isolated by 
Ficoll Hypaque density gradient centrifugation. B cells were immunomagnetically isolated 
from PBMC by positive selection using Dynabeads CD19 pan B (Invitrogen, Leek, the 
Netherlands) and released from the beads using Detach-a-Bead CD19 (Invitrogen). 
This yielded >98% pure B cells, as assessed by flow cytometric analysis. Human B cell 
hybridomas producing a variety of HLA monoclonal antibodies (mAbs) were established 
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as described previously (11). The hybridomas used were SN607D8 (HLA-A2/A28, IgG1), 
BVK5B10 (HLA-B8, IgM), VTM1F11 (HLA-B27/B7/B60, IgG1) and SN66E3 (HLA-A2/A28, 
IgM).
T cells were purified from PBMC by magnetic separation using the Pan T cell isolation 
kit II (Miltenyi, Bergisch-Gladbach, Germany) and MACS MS columns (Miltenyi). Flow 
cytometric analysis revealed >85% purity. 
Proliferation experiments
B cells were cultured for 7 days at 5×103 cells/well in 96-well roundbottom plates (BD 
Falcon, Breda, the Netherlands) in culture medium consisting of IMDM (Gibco, Paisley, 
UK) supplemented with 10% FCS (Gibco), 0.05 mM 2-mercaptoethanol (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) and ITS (insulin 5 µg/ml, transferrin 5 µg/ml and selenium 5 
ng/ml, Sigma-Aldrich) at 37°C and 5% CO2. B cells were stimulated with anti-CD40 mAb (1 
µg/ml, R&D systems, Minneapolis, MN, USA), 100 U/ml IL-2 (EuroCetus, Amsterdam, the 
Netherlands), 25 ng/ml IL-10 (R&D Systems), 100 ng/ml IL-21 (Invitrogen) and 2.5 µg/ml of 
the TLR9 ligand CpG ODN 2006 (Hycult Biotechnology, Uden, the Netherlands). T cells 
were stimulated with 1 µg/ml phytogaemagglutinin (PHA, Remel, Lenexa, KS, USA) and 
cultured at 104 cells/well for 3 days in culture medium without ITS. Autonomously growing 
B cell hybridomas were cultured at 103 cells/well for 5 days in IMDM with 5% FCS, 0.05 mM 
2-mercaptoethanol and 2 mM L-glycyl-L-glutamine (Sigma-Aldrich). 
All cultures were performed in the absence or presence of graded concentrations of IVIg 
(Sanquin, Amsterdam, the Netherlands). Multiple lot numbers of IVIg were used, giving 
comparable results. Proliferation experiments were also performed with Gammagard 
(Baxter, Utrecht, the Netherlands), which gave similar results. Physical properties of the 
IVIg preparations are shown in Table 1. All data shown were obtained with IVIg from 
Sanquin. 
Table 1. Physical properties of IVIg preparations used.
Product Manufacturer Method of preparation % IgG Stabilizing agent
Immunoglobulin i.v. Sanquin Cohn’s cold ethanol fractionation > 95% Glucose
Gammagard S/D Baxter Cohn-Oncley-fractionation, ion-exchange, 
ultrafiltration, chromatography
> 90% Glucose, glycine, 
albumin, PEG
i.v.: intravenous, PEG: polyethylene glycol.
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All IVIg preparations were dialyzed prior to use unless otherwise stated. Dialysis was 
performed in 10 kDa Slide-A-Lyzer cassettes (Pierce, Rockford, IL, USA) against large 
volumes of IMDM. The presence of intact IgG after dialysis was confirmed by ELISA 
(data not shown). Where appropriate, cell culture grade BSA (Calbiochem, La Jolla, 
CA, USA) was used as a control for the high protein concentrations and D(+) glucose 
(Merck, Amsterdam, the Netherlands) was used as a control for the stabilizing agent of 
IVIg. Proliferation was determined by the incorporation of 3H-TdR (1 µCi/well, Amersham 
International, Amersham, UK), added 18 hours before termination of culture. 
Quantitative PCR
For IgM and IgG mRNA detection, B cells were cultured at 5×105 cells per well for 7 days 
in 24-well plates (Costar, Veenendaal, the Netherlands) and stimulated as described above 
in the presence of graded concentrations of IVIg. Rapamycin was used as a control for 
the inhibition of immunoglobulin production (12). Cells were harvested and preserved in 
RNAlater solution (Qiagen, Chatsworth, CA, USA). RNA was extracted using the RNeasy® 
mini kit (Qiagen) following the manufacturer’s instructions. RNA was treated with DNase 
(Qiagen) on the spin columns. RNA quantity was assessed with a spectrophotometer 
(Nanodrop Technologies, Wilmington, DE, USA). All samples showed A260/A280 ratios 
between 1.9 and 2.1. cDNA was synthesized by incubating 12.8 µl RNA solution with 7.2 µl 
cDNA mix containing dNTPs (final concentration of 0.5 mM), 2 U reverse transcriptase-
avian myeloblatosis virus (RT-AMV), 20 U rRNase inhibitor, 100 ng oligo-dT primers, 500 
ng random primers, and 1× reverse transcriptase buffer (all from Promega, Leiden, the 
Netherlands).
Primer sets (Table 2) for quantitative polymerase chain reaction (Q-PCR) were selected 
using Beacon Designer Software (version 7.02, Premier Biosoft International, Palo Alto, 
CA, USA) and obtained from Eurogentec (Liège, Belgium). For the amplification of total 
IgG transcript two forward primers, one hybridizing to the IgG1 sequence and the other to 
IgG2, IgG3 and IgG4 sequences, were used at a 1:1 ratio. The IgG reverse primer detected 
all four IgG variants. PCR mixes contained 1 µM of forward and reverse primers, 3 mM 
MgCl2, and 1× iQ SYBR Green supermix (Bio-Rad, Veenendaal, the Netherlands). The PCR 
was performed using an iCycler MyiQ (Bio-Rad). The PCR program consisted of one cycle 
of 10 min at 95°C, 40 cycles of 15 sec at 95°C and 1 min at 60°C and was finalized with 
a melting curve analysis. Reactions were carried out in optical 96-well plates (Bio-Rad) 
covered with Microseal ‘B’ Film (Bio-Rad). The signal of the stably expressed household 




IVIg fails to inhibit B cell and B cell hybridoma proliferation
IVIg (at concentrations up to 35 mg/ml) failed to affect the proliferative capacity of both 
purified in vitro stimulated B cells from different donors (n=5) as well as four autonomously 
growing B cell hybridomas (Figure 1a and 1b). In contrast, non-dialyzed IVIg did inhibit the 
proliferation of B cell hybridomas (Figure 1c), which is in agreement with published data 
(13). However, inhibition was not due to the immunoglobulin component, as is clear from 
the lack of proliferation inhibition with dialyzed IVIg, but rather caused by the stabilizing 
agent glucose that is present in the IVIg solution (Figure 1d).
Since IVIg has been described to inhibit mitogen-induced lymphocyte proliferation (14), we 
tested its capacity to inhibit PHA induced T cell proliferation (n=4). The IVIg preparation 
dose-dependently inhibited T cell proliferation, indicating that the IVIg preparation was 
functional (Figure 1e). This inhibition was not due to high protein concentration, as shown 
by the inability of comparable concentrations of BSA to inhibit proliferation (Figure 1f).
IVIg does not inhibit immunoglobulin mRNA levels
Previously, we showed that B cells cultured in the presence of anti-CD40 mAb, IL-2, IL-10, 
IL-21 and CpG ODN 2006 were capable of producing large quantities of both IgM and IgG 
(12). This stimulation protocol induced vast elevations in mRNA levels for both IgM and 
IgG when compared to unstimulated B cells (Figure 2a and 2b), which is in concordance 
with immunoglobulin levels measured in the supernatants of these B cell cultures by ELISA 
(data not shown). 
To test the effect of IVIg on immunoglobulin production, B cells were stimulated in the 
presence of IVIg at graded concentrations up to 35 mg/ml. Rapamycin was used as positive 
control for the reduction of immunoglobulin production. Q-PCR with primers specific 
for IgM and IgG revealed that IVIg did not affect the levels of IgM or IgG mRNA, whereas 
rapamycin dose-dependently reduced IgM and IgG mRNA levels (Figure 3a and 3b).
Table 2. Sequences for primers used in quantitative polymerase chain reaction (Q-PCR).
Transcript Forward primer Reverse primer Amplicon
IgG1 CATCTCCAAAGCCAAAGG ATGTCGCTGGGATAGAAG 126 bp
IgG2-4 CATCTCCAAAGCCAAAGG ATGTCGCTGGGGTAGAAG 126 bp
IgM CAGGGCACAGACGAACAC CGGCAATCACTGGAAGAGG 85 bp
18S rRNA AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC 68 bp
bp: base pairs.
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Figure 1. IVIg does not reduce the proliferative capacity of B cells and B cell hybridomas, whereas mitogen-induced 
T cell proliferation is inhibited. Non-dialyzed IVIg does inhibit hybridoma proliferation, caused by the stabilizing agent 
glucose. (a) B cells were cultured at 5×103 cells/well with the addition of anti-CD40 mAb, IL-2, IL-10, IL-21 and CpG ODN 
2006 in the presence of graded concentrations of IVIg. Connecting lines represent the individuals donors (n=5) tested. (b) 
Autonomously growing B cell hybridomas were cultured at 103 cells/well in the presence of graded concentrations of IVIg, 
(c) non-dialyzed IVIg or (d) glucose in concentrations similar to the IVIg solution. Connecting lines represent individual 
hybridomas. Representative experiments are shown. (e) T cells were isolated by MACS isolation and cultured at 104 
cells per well with 1 mg/ml PHA in the presence of graded concentrations of IVIg or (f ) BSA in concentrations equal to 
the IVIg solution. Connecting lines represent the individuals donors (n=4) tested. Proliferation was measured by 3H-TdR 




IVIg is known to have a wide range of clinical effects. When used in vitro, IVIg reduced the 
reactivity of serum HLA antibodies (15, 16). It also inhibited mixed lymphocyte responses, 
and mitogen induced PBMC and T cell proliferation (14), as well as T cell dependent B cell 
responses (17-20). 
The present study shows that IVIg does not affect the proliferative capacity of polyclonally 
stimulated purified B cells. This lack of inhibition is not due to extremely high B cell 
stimulation that is no longer amenable to interference, since we have previously shown 
that relatively low levels of standard immunosuppressive drugs can completely abolish 
proliferation, as well as immunoglobulin production of B cells stimulated with the same 
protocol (12). In contrast to the lack of B cell proliferation inhibition by IVIg, mitogen-
induced T cell proliferation was significantly inhibited by the same IVIg preparation, 
indicating that the IVIg preparation was effective. This inhibition was not due to high 
protein levels, indicating that immunoglobulins present in the IVIg preparation were the 
cause of proliferation inhibition. 
Figure 2. B cell activation induces IgM and IgG mRNA levels. B cells were activated with anti-CD40 mAb, IL-2, IL-10, IL-
21 and CpG ODN 2006 and the cells were harvested at different time-points after activation. IgM (a) and IgG (b) mRNA 
levels were assessed by quantitative PCR. Unstimulated cells were harvested at day 0 and served as negative control. 
The results of one representative experiment are shown. Similar results were obtained in 4 independent experiments.
B cell hybridomas were previously shown to be inhibited by a non-dialyzed IVIg preparation 
(13). We added non-dialyzed IVIg to similar B cell hybridomas and observed a comparable 
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inhibition. However, when we dialyzed the IVIg prior to use to remove stabilizing agents 
such as glucose from the solution, the inhibition was abrogated. In agreement with previous 
studies (21), addition of glucose in concentrations similar to those in the IVIg preparation 
did inhibit the proliferation of B hybridomas. These data underscore the importance of 
dialysis of the IVIg preparation for in vitro studies.
Figure 3. IVIg does not affect the mRNA synthesis of IgM and IgG, whereas rapamycin does inhibit IgM and IgG mRNA 
levels. B cells were stimulated with anti-CD40 mAb, IL-2, IL-10, IL-21 and CpG ODN 2006 and cultured in the presence 
of graded concentrations of IVIg (a). Control cultures were performed with graded concentrations of rapamycin. mRNA 
levels for IgM and IgG were quantified using quantitative PCR (b). The dotted lines represent the mRNA steady state 
level in stimulated, non-treated B cells. Data from 3 experiments with different donors are shown. Depicted are the 
percentages of IgM and IgG mRNA expression, relative to the mRNA expression of untreated controls. Statistics: paired 
T test, *P<0.05; **P<0.01 and ***P<0.001. 
Besides B cell proliferation, studying the effects of IVIg on immunoglobulin production 
is of particular interest, since anti-idiotypic antibody binding and binding to inhibitory Fc 
receptors are candidate mechanisms for interference with immunoglobulin production (6, 
7). 
Unfortunately, the high IgG content of IVIg precludes the detection of newly synthesized IgG 
by standard ELISA techniques. De Grandmont et al. circumvented this issue by radioactive 
labeling of secreted immunoglobulins followed by capture with anti-IgG antibodies (22). But 
even then, competition by IVIg for capture antibody cannot be excluded. Therefore, we 
designed a novel approach to indirectly measure immunoglobulin production by detection 
of IgM and IgG mRNA levels. We found that IVIg does not affect the mRNA synthesis of 
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both IgM and IgG by stimulated B cells. It seems therefore highly unlikely that IVIg directly 
influences immunoglobulin production.
This conclusion is at variance with other studies that do show an inhibitory effect of IVIg 
on immunoglobulin production (17-20). These studies, which describe B cells as targets 
for IVIg, were performed with Pokeweed Mitogen stimulation, which is a model of T cell 
dependent antibody production by B cells (23). However, it cannot be ruled out that in 
that culture system IVIg interferes with the actual stimulus, i.e. Pokeweed Mitogen, rather 
than that it truly inhibits B cell functions. In another study, inhibition of proliferation and 
IgE secretion of purified tonsillar B cells cultured with IL-4 and anti-CD40 was described 
(24). However, these results were obtained using a non-dialyzed IVIg preparation, and are 
likely an effect of the stabilizing agents in the IVIg preparation. 
IVIg preparations differ greatly in terms of production process and Ig content. While B cell 
inhibitory effects were not found in two different IVIg preparations, it cannot be ruled out 
that other preparations will show inhibitory effects, particularly when other isotypes are 
present, as in Pentaglobulin.
In line with our results, a series of in vivo studies show the lack of direct effects on 
immunoglobulin producing cells. IVIg was unable to reduce B cell and plasma cell numbers 
in human splenic follicles (25). Furthermore, IVIg failed to reduce the number of bone 
marrow residing long-lived plasma cells producing HLA-specific antibodies (26).
The inhibitory effect of IVIg on humoral immunity may therefore be explained by alternative 
mechanisms, such as inhibition of T cell help, interaction with circulating antibodies and 
interaction with complement factors. Inhibitory effects of IVIg on T cell priming by 
dendritic cells have been described (27), as well as cytokine-dependent T cell proliferation 
(28). Inhibition of T cell function may lead to insufficient generation of helper T cells, which 
affects B cell responses. Future research on the effect of IVIg on T cell help directly, and 
on T cell dependent B cell responses in co-culture systems will provide more insight in the 
effect of IVIg on humoral immune responses.
Interaction of the variable regions of IVIg with variable regions of autoantibodies of 
multiple specificities has been described (29, 30), suggesting anti-idiotypic activity of IVIg. 
Circulating anti-HLA antibodies may be subject to the same mechanism of suppression. 
In addition, interference of IVIg with complement activation (8, 31) and impairment of 
monocyte Fc receptor functions (9) have been suggested. These mechanisms may affect 
the action of deleterious complement binding antibodies and/or phagocytosis, leading to 
protection from immune damage. Alternatively, saturation of the FcRn receptor may be 
involved in clearance of pathogenic antibodies (10).
Taken together, our results show that IVIg fails to directly act on immunoglobulin producing 
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cells. The capability of IVIg to interfere with humoral immunity is therefore more likely 
due to effects on T cells and interactions with circulating antibodies and/or complement 
factors.
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The proteasome inhibitor bortezomib is a potent inducer of apoptosis in malignant (1) as 
well as non-malignant human plasma cells (2). For that reason, bortezomib has recently 
come to the attention of the transplantation community for the treatment of humoral 
rejection. Bortezomib was shown to reduce donor specific antibody levels and effectively 
revert rejection episodes (3, 4), as well as attenuate HLA antibody levels in non-rejecting 
transplant patients (5). Since proteasomes are present in all eukaryotic cells, bortezomib, 
besides its effects on plasma cells, likely affects other cell types of the immune system 
as well. Additional drug effects towards B cells may be beneficial for the treatment of 
humoral rejection. Therefore, we tested whether, in addition to plasma cell depletion, 
bortezomib was capable of inhibiting the functionality of human B cells upon CD40 or B 
cell receptor mediated stimulation. 
MATERIALS AND METHODS
Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll Hypaque density gra-
dient centrifugation from blood of healthy blood bank donors after informed consent. B 
cells were immunomagnetically isolated by positive selection (Invitrogen, Leek, the Neth-
erlands). These CD19+ B cells were cultured in Iscove’s Modified Dulbecco Medium (Gib-
co, Paisley, UK) supplemented with 10% FCS (Gibco), 0.05 mM 2-mercaptoethanol (Sigma-
Aldrich, Zwijndrecht, the Netherlands) and ITS (Sigma-Aldrich) at 37°C and 5% CO2. B 
cells were activated with 1 µg/mL of anti-CD40 mAb (R&D systems, Minneapolis, MN, 
USA), 100 U/mL of IL-2 (EuroCetus, Amsterdam, the Netherlands), 25 ng/mL IL-10 (R&D 
systems), 100 ng/ml of IL-21 (Invitrogen) and 2.5 µg/ml of the TLR9 ligand CpG ODN 2006 
(Hycult Biotechnology, Uden, the Netherlands), or with 1:10.000 diluted Staphylococcus 
aureus (Calbiochem, La Jolla, CA, USA) with 5% v/v supernatant of phytohaemaglutinin 
(PHA) activated T cells, prepared as described before (6). At day 6, supernatants were col-
lected for IgM and IgG detection by ELISA (7). The incorporation of 3H-TdR (Amersham 
International, Amersham, UK, 1 µCi/well added during the last 18 h of a 7 day culture) was 




Bortezomib completely abrogated IgM and IgG production as well as proliferation in a 
dose dependent fashion. Complete inhibition of immunoglobulin production was achieved 
at 1.0 ng/ml of bortezomib with IgM and IgG levels equally influenced (Figure 1a). Prolif-
eration was already completely inhibited at 0.75 ng/ml of bortezomib. Additionally, when 
added to B cells that were already activated for 2 days, bortezomib completely inhibited 
proliferation, albeit at slightly higher doses (Figure 1b). Bortezomib also inhibited immu-
noglobulin production and proliferation of Staphylococcus aureus stimulated B cells (data 
not shown), indicating that this is a general effect of bortezomib on B cells, regardless of 
the mode of stimulation.
We conclude that, in addition to depleting plasma cells, bortezomib profoundly abrogates 
B cell function. Thus, bortezomib may prevent the de novo emergence of HLA antibodies 
as well as deplete an important source of antigen presenting cells. Our findings suggest 
that, when bortezomib is used for desensitization or for the treatment of humoral rejec-
tion, there is no need for additional anti-B cell therapy, such as anti-CD20 mAb treatment.
Figure 1. Bortezomib effectively inhibits immunoglobulin production and proliferation of activated human B cells. Iso-
lated B cells were cultured at 5×103 cells per well in 96-wells round bottom plates for 7 days in the presence of graded 
concentrations of bortezomib. At day 6, supernatants were collected for immunoglobulin (Ig) detection. Bortezomib 
dose-dependently inhibited IgM and IgG levels in B cell cultures (a). After 7 days of culture, B cell proliferation was mea-
sured by 3H-TdR incorporation. Bortezomib added either directly (t= 0 h), or after 2 days (t= 48 h) dose-dependently 
inhibited B cell proliferation (b). Data are depicted as means of at least triplicate wells with standard deviation. Repre-
sentative data from one experiment are shown; similar results were obtained in four independent experiments. CPM: 
counts per minute.
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Quantification of the humoral alloimmune response is generally achieved by measuring 
serum HLA antibodies, which provides no information about the cells involved in the hu-
moral immune response. Therefore, we have developed an HLA-specific B cell ELISPOT 
assay allowing for quantification of B cells producing HLA antibodies. 
We used recombinant HLA monomers as target in the ELISPOT assay. Validation was 
performed with human B cell hybridomas producing HLA antibodies. Subsequently, we 
quantified B cells producing HLA antibodies in HLA-immunized individuals, non HLA-
immunized individuals and one transplant patient with serum HLA antibodies. 
B cell hybridomas exclusively formed spots against HLA molecules of corresponding speci-
ficity with similar sensitivity to total IgG ELISPOT assays. HLA immunized healthy individu-
als had up to 182 HLA-specific B cells per million total B cells. In contrast, non-immunized 
individuals did not form spots. A kidney transplant patient who was immunized by an HLA-
A2-mismatched graft had 143 HLA-A2-specific B cells per million total B cells.
In conclusion, we have developed a highly specific and sensitive HLA-specific B cell ELISPOT 
assay, which can be used to determine the frequency of peripheral HLA-specific B cells 
in transplant patients. This technique provides an alternative way to quantify humoral im-
mune responses.
 




In organ transplantation, B cells can be harmful to a transplanted organ mostly by their 
antibody producing capacity. The presence of HLA antibodies is associated with allograft 
rejection, since their development frequently precedes chronic rejection in renal trans-
plantation (1, 2).
Techniques for the analysis of donor-specific serum HLA antibodies are widely available 
and include complement dependent cytotoxicity (CDC) (3), ELISA (4, 5), flow cytometry 
(6) and Luminex-based assays (7). These assays are valuable for determination of donor-
specific antibodies in the circulation, but are likely to underestimate the magnitude of the 
humoral immune response in the case of antibody absorption by the graft (8). Therefore, 
assessing the frequency of circulating HLA specific B cells may provide a more accurate 
estimate of the humoral immune status of a patient. Moreover, the demonstration of an 
increment of B cell numbers with anti-donor specificity may be taken as a predictor of 
antibody formation in the case that an incipient B cell response is not yet detectable as 
serum HLA antibodies.
Assays to quantify the number of cells contributing to alloantibody production are scarce. 
We previously described a technique to estimate the B cell precursor frequency (BCPF) 
of B cells with HLA-specificity (9). This laborious technique only allows for the quantifica-
tion of B cells producing complement-fixing antibodies. However, non-complement-fixing 
antibodies may play a role in humoral rejection (10, 11). The inability to detect comple-
ment-fixing antibodies is circumvented by an alternative technique in which HLA-specific 
B cells from CD19-enriched cell populations are stained with tetramers, quantifying B cells 
harboring a B cell receptor (BCR) directed against certain HLA molecules (12, 13). A disad-
vantage of this technique, which relies on binding of the BCR to HLA tetramers, is that it 
does not readily provide information on the proportion of cells actually capable of produc-
ing antibodies. Alternatively, an elegant technique for the quantification of bone-marrow 
residing plasma cells producing HLA antibodies has been described (14). However, bone 
marrow is not regularly available from transplant patients, which makes this technique 
unsuitable for routine screening purposes.
Here, we describe a novel technique to detect and enumerate HLA-specific memory B 
cells that are capable of producing antibodies. The assay is performed on B cells from 
peripheral blood, which is routinely collected before and after transplantation in many 
transplant centers. The HLA-specific B cell ELISPOT enables longitudinal post-transplant 
monitoring of humoral HLA-specific immunity, and may assist in tailoring the immunosup-





The subject population consisted of 10 HLA-A2-immunized, 3 HLA-B7-immunized and 
3 HLA-A1-immunized multi- and uniparous healthy individuals, 11 healthy control blood 
donors and 1 kidney transplant patient. The immunized healthy individuals had developed 
serum HLA-A2, HLA-B7 or HLA-A1 antibodies by pregnancy, as determined by CDC. 
The control blood donors either had an HLA-type similar to the HLA molecule to which 
they were tested, or an HLA-type different from the HLA molecule to which they were 
tested, but not sensitized to HLA. The kidney transplant patient (HLA-A2-) was on the 
waiting list for a transplant after having rejected a previous, HLA-A2 mismatched, graft. 
This patient had developed serum antibodies towards HLA-A2 during the rejection, which 
were still present at time of sampling.
Cells
Blood was obtained with informed consent under guidelines issued by the Medical Ethics 
Committee of the Leiden University Medical Center (Leiden, the Netherlands). Peripheral 
blood mononuclear cells (PBMC) were isolated by Ficoll Hypaque density gradient centrif-
ugation. To retrieve as many B cells as possible, we partially depleted T cells from PBMC, 
rather than positively isolating the B cell fraction (12). To this goal, we incubated PBMC 
with magnetically labeled CD2 Microbeads (Miltenyi, Bergisch-Gladbach, Germany), fol-
lowed by magnetic cell separation. Flow cytometry (FCM), using CD19-PE (BD Bisosci-
ences, Breda, the Netherlands) revealed, on average, a 6-fold enrichment of CD19+ B cells. 
The CD2- cell population will be referred to as enriched B cell population.
The human monoclonal antibody (mAb) producing B cell hybridomas GV5D1 (IgG, HLA-
A1/A9), SN607D8 (IgG, HLA-A2/A28), MUL2C6 (IgG, HLA-A3/A11/A24), VTM1F11 (IgG, 
HLA-B27/B7/B60) and BVKF9 (IgG, HLA-B8) were developed as described previously (15) 
and used for optimization and validation of the HLA-specific ELISPOT assays. The human 
CD40L expressing murine fibroblast cell line L-CD40L was used to activate B cells (16).
Monomeric HLA molecules
The HLA-A*0101 monomer was constructed around the melanoma associated MAGE3 
peptide (sequence: EVDPIGHLY), the HLA-A*0201 monomer was constructed around 
the melanoma associated MART-1 peptide (sequence: ELAGIGILTV), the HLA-A*301 
monomer around the MAGE1 melanoma peptide (sequence: SLFRAVITK), the HLA-
A*1101 monomer around the EBV derived EBNA3B peptide (sequence: AVFDRKSDAK) 
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and the HLA-B*0702 monomer around the hCMV derived pp65 peptide (sequence: 
RPHERNGFTV) as described previously (17).
Cell culture
Enriched B cells were cultured for 7 days at 2.5×105 cells per well in 24-well plates (Co-
star, Veenendaal, the Netherlands) in culture medium consisting of IMDM (Gibco, Paisley, 
UK) supplemented with 10% FCS (Gibco), 0.05 mM 2-mercaptoethanol (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) and ITS (insulin 5 µg/ml, transferrin 5 µg/ml and selenium 
5 ng/ml, Sigma-Aldrich) at 37°C and 5% CO2. Cells were stimulated with irradiated (75 
Gy) L-CD40L cells with 40 U/ml IL-2 (EuroCetus, Amsterdam, the Netherlands), 10 ng/ml 
IL-10 (R&D systems, Minneapolis, MN), 10 ng/ml IL-21 (Invitrogen, Leek, the Netherlands) 
and 1 µg/ml of the TLR-9 ligand ODN-2006 CpG (Hycult Biotechnology, Uden, the Neth-
erlands). At day 7, supernatants were collected and frozen at -20°C until further use and 
cells were harvested for FCM and for use in the ELISPOT assay.
ELISPOT assay
We used a previously established total IgG ELISPOT assay for detecting total numbers of 
IgG producing B cells (18) and developed an HLA-specific ELISPOT assay for enumerat-
ing the number of HLA-specific B cells. For measuring total IgG spots, ELISPOT plates 
(Millipore, Amsterdam, the Netherlands) were coated with goat anti-IgG (Jackson Immu-
noresearch, Suffolk, UK) in PBS overnight at 4°C and blocked with 5% FCS/IMDM at 37°C 
for 2 h. For detecting HLA-specific B cells, ELISPOT plates were coated with Streptavidin 
(Pierce, Rockford, IL, USA) in 10 mM Tris pH 9.0 overnight at 4°C, followed by 4 h incuba-
tion of a biotin labeled HLA class I monomer at 500 ng/well as capture matrix in PBS at RT 
and blocking with 5% FCS/IMDM at 37°C for 1 h. To make sure no aspecific background 
spots were counted in the ELISPOT, we included wells coated with streptavidin, but with-
out monomer. Spots, if any, in these control wells were of low intensity, and spot numbers 
in these control wells were deducted from spot numbers counted in wells with monomer 
present.
B cell hybridomas were harvested, thoroughly washed, diluted in a range of cell con-
centrations in 5% FCS/IMDM with 200 U/ml penicillin and 200 µg/ml streptomycin, and 
transferred to wells of anti IgG- and HLA-monomer coated ELISPOT plates. Activated 
enriched B cells were similarly treated but seeded at 2.5×105 cells per well in multiple wells 
of ELISPOT plates. After overnight incubation at 37°C, plates were thoroughly washed and 
incubated for 2 h at RT with HRP conjugated goat anti-IgG (Southern Biotech, Birming-
ham, AL). Plates were washed and incubated with TMB substrate (Mabtech, Nacka Strand, 
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Sweden) for 5 min. The reaction was stopped by rinsing with water. Plates were analyzed 
using a computer guided ELISPOT reader (iSPOT system, AID, Strassberg, Germany). 
To calculate the ratio of HLA-specific B cells per million total input B cells, the percentage 
live B cells (based on forward/sideward scatter and CD19 FCM positivity) present in the 
pre-culture at day 7 was used to calculate the ratio of HLA-specific B cells per million total 
B cells as follows:
HLA-specific antibody detection
Supernatants from enriched B cell pre-cultures were tested for the presence of antibodies 
against HLA-A2 in a Luminex assay using LABScreen beads (OneLambda, Canoga Park, 
CA) following the manufacturer’s description. Beads carrying A*0201 molecules (batch 
LS1A04NC8_005_00) were used to detect HLA-A2 antibodies. As negative control we 
used the LABScreen negative control serum (LS-NC, OneLambda). Samples were mea-
sured using a Luminex Bio-plex 100 reader (Bio-Rad, Veenendaal, the Netherlands).
Statistics
To compare the difference between spot numbers of HLA-immunized and non-immunized 
individuals, the Wilcoxon Rank test was used. Statistical level of significance was defined 
as P<0.05.
RESULTS
ELISPOT specificity and detection level
Mixing experiments of HLA-A2 specific B cell hybridomas with hybridomas of other speci-
ficity were performed to determine the specificity of the ELISPOT assay with HLA-A2 
monomers as capture matrix. We observed titratable spots when using HLA-A2-specific 
hybridomas, whereas background levels of spots were observed when using a hybridoma 
with other specificity (Figure 1a). Additionally, we tested the specificity of the assay using 
an HLA-A1 specific hybridoma mixed with a hybridoma of other specificity in an ELISPOT 
assay with a HLA-A1 monomers as capture matrix. Similar to the HLA-A2 ELISPOT, HLA-
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A1 specific hybridomas generated spot formation, whereas hybridomas of other specificity 
did not (Figure 1b). Specificities of ELISPOT assays using HLA-A3 and HLA-A11 monomers 
as capture matrix were similar to those of HLA-A2 and HLA-A1 (data not shown). We 
corroborated the specificity of the ELISPOT assay by testing HLA-A2- healthy individuals 
who were immunized by pregnancy towards HLA-A2, but not towards HLA-A1 or HLA-
A11, in ELISPOT assays with these HLA molecules as targets. We observed spots against 
HLA-A2, but not against HLA-A1 or HLA-A11, warranting that the ELISPOT assay is highly 
specific (Figure 1c).
To make sure that the HLA-specific ELISPOT assay was able to detect all cells producing 
HLA-specific immunoglobulins, we compared the spot count of the total IgG ELISPOT 
with spot count of the HLA-specific ELISPOT within the same experiment. The HLA-spe-
cific ELISPOT with HLA-A2 as antigen was able to detect all HLA-A2 antibody producing 
cells, since the number of spots detected in the total Ig ELISPOT and the HLA-A2 specific 
ELISPOT were comparable (Figure 2). Identical results were obtained when using HLA-
A11 specific hybridomas in an HLA-A11 ELISPOT assay (data not shown).
Figure 1. The HLA-specific ELISPOT assay is highly specific.  (a) An IgG producing HLA-A2 specific B cell hybridoma 
(SN607D8) was mixed with an IgG producing HLA-B27/B7/B60 specific B cell hybridoma (VTM1F11) in various ratios. 
(b) An IgG producing HLA-A1 specific B cell hybridoma (GV5D1) was mixed with an IgG producing HLA-B8 specific B 
cell hybridoma (BVK1F9) in various ratios. (c) B cells from a healthy individual (HLA class I typed A3, B7, B15, Cw3, Cw7), 





HLA-specific B cells are detected in HLA-immunized individuals
To determine whether the HLA-specific ELISPOT assay was capable of detecting human 
B cells producing HLA-specific immunoglobulins, we made use of PBMC from healthy 
women who were HLA-A2-immunized by pregnancy. HLA-A2+ individuals and HLA-A2-, 
non-HLA-A2 immunized individuals were used as negative controls. In individuals who 
were HLA-immunized by pregnancy, we found HLA-A2 specific B cells ranging from 0 to 
125 cells per million total B cells (median=14, n=10), whereas in HLA-A2+ (n=3) and HLA-
A2- non-immunized individuals (n=3) the number of spots ranged from 0 to 1 per million 
total B cells  (median=0, Figure 3).  In HLA-A1-immunized individuals we observed spots 
Figure 2. The HLA-specific ELISPOT is able to recognize all antibody-producing cells of corresponding specificity. The 
IgG producing HLA-A2 specific B cell hybridoma SN607D8 was titrated to be able to compare the HLA-specific ELISPOT 
(panel a) and the total IgG ELISPOT (panel b) for the number of spots.
ranging from 5 to 42 spots per million B cells (median=40, n=3), and no spots in HLA-A1+ 
and HLA-A1-, non-immunized individuals (n=3). Finally, in HLA-B7-immunized individuals 
we observed frequencies ranging from 9 to 182 spots per million B cells (median=109, 
n=3), whereas in control experiments with HLA-B7+ individuals and HLA-B7-, non sensi-
tized individuals we observed no spot formation (n=3). 
To ensure that spots detected in the ELISPOT assay were truly formed against corre-
sponding HLA molecules, we performed a Luminex assay to detect HLA-A2 specific anti-
bodies in the supernatants of the pre-culture of selected individuals who developed spots 
in an HLA-A2-specific ELISPOT assay. In those cases where we found spots against HLA-
A2, we detected HLA-A2 specific antibodies in corresponding supernatants (Table 1). 
(a) (b)
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Interestingly, in the one pregnancy-immunized individual where we did not observe spots 
against HLA-A2, we also did not find HLA-A2 specific antibodies in the supernatant of 
the pre-culture. No correlation between the number of spots and the mean fluorescence 
intensity (MFI) was observed.
Detection of HLA-A2 specific B cells in transplant patients
Since the HLA-immunized individuals we tested in the ELISPOT assay were immunized by 
pregnancy, we wanted to confirm the ability to detect HLA specific B cells in individuals 
who had developed HLA antibodies due to allograft rejection. One HLA-A2- kidney trans-
plant patient who was on the waiting list for a transplant after having rejected a previous, 
Individual Immunization    ELISPOT results    Frequency
70a  A2-immunized        99
   
71b  A2-immunized        6
70b  non-immunized        0
 
71d  non-immunized        0
(a)
(b)
Figure 3. HLA-specific B cells are detected in HLA-immunized individuals, but not in non-immunized individuals. (a) 
Raw ELISPOT data of 2 HLA-A2 immunized and 2 non-immunized individuals. Frequency is the number of spots per 
million B cells. (b) Enriched B cells were activated for 7 days and seeded into ELISPOT plates coated with HLA-A2 
monomers. Depicted are the number of HLA-A2 specific antibody producing B cells per million total B cells of HLA-A2 
immunized and non-immunized healthy individuals, as well as the number of HLA-A1 spots measured in HLA-A1-specific 




Table 1. HLA-A2 spot numbers and MFI values of HLA-A*0201 specific Luminex.
Individual Immunization status Spot numbera MFI supernatant MFI negative control
70a A2-immunized 99 59.79 0.98
71a A2-immunized 0 0.00 0.76
71b A2-immunized 6 61.80 0.75
73a A2-immunized 8 112.18 1.48
73b A2-immunized 24 140.22 1.00
70b non-immunized 0 0.00 1.14
71c non-immunized 1 0.00 2.91
71d non-immunized 0 0.00 1.10
73d non-immunized 0 3.90 0.90
aPer million total B cells. 
MFI: mean fluorescence index.
DISCUSSION
Monitoring of the immune status after transplantation can be of great benefit to patients, 
since it may be of help in determining taylor-made immunosuppressive protocols. Tech-
niques for the assessment of the cellular immune status are manyfold and have been in use 
for a considerable time. These include the mixed lymphocyte reaction (MLR), the cyto-
toxic T cell precursor assay (CTLp) (19), IFN-γ and IL-10 ELISPOT assays (20) as well as 
phenotypic analysis by flow cytometry. For humoral immunity, the main techniques used 
are to detect serum antibody levels (3-7), but not the (potential) activity of alloantibody-
producing cells.
Upon encounter with antigen, B cells can form germinal centers in which memory B cells 
and plasma cells are generated. Plasma cells subsequently migrate to the bone marrow 
where they produce antibodies. A fraction of memory B cells circulate in the peripheral 
blood, where they make up about 30% of total CD19+ B cells (21, 22). The use of an 
ELISPOT technique was already described for quantifying human antigen-specific memory 
B cells from peripheral blood specific for an antigen of an Anthrax vaccine (22) and for 
the analysis of B cell memory towards antigens of the Malaria causing parasite Plasmodium 
falciparum (23) and HIV antigens (24). Here we present a validated technique to quantify 
HLA-A2 mismatched, graft was tested for the presence of HLA-A2 specific B cells. We 
found  a frequency of 143 HLA-A2-specific B cells per million total B cells (data not shown).
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HLA-specific memory B cells of several specificities from peripheral blood.
To be able to detect HLA-specific B cells with specificity towards certain HLA molecules, 
we used recombinant monomeric HLA molecules as a source of pure HLA antigen. We 
previously showed the capability of HLA-specific B cells to recognize MHC class I tetra-
mers, as well as the specific recognition of HLA-A2 tetramers by monoclonal B cell hybrid-
omas producing HLA-A2 antibodies (25). This provided a rationale for using recombinant 
monomeric MHC class I molecules as antigen in the ELISPOT assay. The specificity of the 
assay was determined by using B cell hybridomas, which produce antibodies towards de-
fined HLA molecules. The unambiguous specificity of hybridomas for their corresponding 
MHC class I monomer in the HLA-specific B cell ELISPOT assay is in concordance with 
previous data from our laboratory, in which tetrameric MHC class I molecules were used 
to stain a panel of beads that were coated with mAbs derived from these hybridomas (26).
Recombinant MHC molecules are routinely loaded with peptides from a single specific-
ity, allowing for the detection of specific T and/or B cell subsets in a variety of assays. We 
have previously shown that the embedded peptide affects binding of human HLA-specific 
mAbs (27). In contrast, Barnardo et al. did not observe an effect of different peptides on 
the binding of sera from HLA-immunized individuals to HLA monomers in an ELISA assay 
(28). Additionally, Zachary and colleagues have shown no effect of the HLA-bound peptide 
on tetramer staining of polyclonal B cells (12). Similarly, in the ELISPOT assay we found 
in preliminary tests that the use of a single monomeric HLA-A2 molecule resulted in the 
same number of spots as compared to a pool of 3 monomeric HLA-A2 molecules with 
different peptides (data not shown). It is therefore likely that a B cell alloresponse includes 
sufficient numbers of clones to surpass the contribution of single clones. As such, to be 
able to identify HLA-specific B cells in an HLA-immunized individual, the use of single re-
combinant monomeric MHC molecules is likely to be sufficient.
The demonstration that the detection of HLA-specific B cells by the ELISPOT corre-
sponded to the presence of HLA-antibodies in the supernatant of pre-cultures warrants 
that the B cells truly produce anti-HLA antibodies. As expected from the relatively low 
HLA-specific B cell frequency, Luminex MFI values were low compared to positive control 
serum generated values (mean MFI: 3012.75), but considerably elevated compared to the 
negative control. Furthermore, the data showing that HLA-A2-, non-immunized individu-
als lack spot formation against HLA-A2 monomers as well as HLA-A2 specific antibodies 
in the pre-culture ensures that positive signals are due to memory, and not naïve, B cell re-
sponses. The lack of correlation between the number of A2-specific spots in the ELISPOT 
assay and the A2-specific immunoglobulin levels in the Luminex assay suggest that antibody 
producing B cell clones differ in the amount of immunoglobulin produced.
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HLA-specific B cells in transplant patients under immunosuppression can be detected 
using the current ELISPOT assay, indicating that this technique is suited for assessing the 
HLA-specific humoral immune status in transplant patients. Additional studies on PBMC 
from transplant patients collected at set time-points are currently performed to extend 
these data and to determine whether the HLA-specific ELISPOT can predict humoral 
rejection. Moreover, we are rapidly expanding the number of HLA antigens that can be 
used in our ELISPOT assay to provide a comprehensive panel of HLA-specific B cells to 
be detected.
Recently, Wadia et al. published an article containing preliminary data claiming the develop-
ment of an HLA-specific B cell ELISPOT (29). However, no data were shown on the speci-
ficity and sensitivity of this assay. Therefore, to our knowledge, ours is the first report of 
a well-validated, reproducible HLA-specific B cell ELISPOT. This assay may be a useful tool 
for monitoring transplant patients for their HLA-specific B cell load. More importantly, it 
may allow the detection humoral rejection at an early stage, preceding the emergence of 
serum HLA antibodies. Whether this is the case, will be subject to further studies.
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Monitoring of T cells involved in an alloimmune response requires the presence of in 
vitro assays, which can detect T cells with direct as well as indirect allospecificity. While 
generally accepted assays exist to measure helper and cytotoxic T cells involved in direct 
allorecognition, consensus about an assay for monitoring indirect T cell allorecognition in 
clinical transplantation is lacking. Many studies claim a relationship between the reactivity 
of T cells with indirect allospecificity and allograft rejection, but different approaches are 
used and often, essential controls are lacking. In this review, the disadvantages and pitfalls 
of the different approaches used so far are discussed and supported by our own in vitro 
experiments. We conclude that an international workshop is necessary to establish and 
validate a uniform, robust and reliable assay for the monitoring of transplant recipients and 
to study the actual role of indirect allorecognition in acute and chronic rejection. 




Transplantation, blood transfusion or pregnancy may result in activation of alloreactive T 
cells leading to rejection, graft versus host disease and/or induction of IgG alloantibodies. 
These alloreactive T lymphocytes recognize non-self antigens, mostly derived from the 
highly polymorphic major histocompatibility complex (MHC) on allogeneic cells or tissue. 
The way by which T lymphocytes recognize alloantigens has been the focus of many stud-
ies and can occur by two distinct, not mutually exclusive pathways: the direct and indirect 
pathway.
Direct allorecognition refers to the recognition of intact allo-MHC molecules expressed 
on the surface of donor antigen-presenting cells (APCs). Allorecognition in this way results 
in a vigorous immune response, due to the high precursor frequency of T cells involved in 
this pathway (1). Two hypotheses have been proposed for this T cell activation, referred 
to as the ‘high determinant density model’ and the ‘multiple binary complex model’. In the 
high determinant density model it is presumed that every MHC molecule on the cell sur-
face, irrespective of the bound peptide, can serve as a ligand for host alloreactive T cells. 
The high antigen density may thus account for the vigorous immune response. In the mul-
tiple binary complex model, the peptide bound in the groove of the allo-MHC molecule 
is the decisive entity. Here, each peptide-allo-MHC complex is recognized by a unique 
host alloreactive T cell, also leading to a strong immune response. It is obvious that direct 
allorecognition only occurs after transfer of tissues or cells between genetically different 
individuals. In contrast, the mechanism of indirect allorecognition is basically not different 
from MHC restricted recognition of virally encoded antigens.
Indirect allorecognition is the stimulation of recipient T lymphocytes by processed donor 
antigens presented as peptides in the context of self-MHC. Evidence for this alternative 
pathway of T cell allorecognition came from observations that graft rejection still occurred 
in the absence of immunogenic donor-derived passenger cells in the graft (2). Alloantigens 
shed from the graft are internalized and processed in the same way as exogenous antigens 
and presented by recipient APCs as peptides in self-MHC class II molecules to CD4+ T 
cells. The frequency of T cells with indirect allospecificity is two orders of magnitude 
lower than T cells directly recognizing alloantigens, and the maximal response in the indi-
rect pathway developes later (3).
To gain more insight into these alloimmune responses and eventually control them, it is 
essential to develop reliable in vitro assays to monitor the magnitude and specificity of a T 
cell alloimmune response. Although assays such as the mixed lymphocyte culture (MLC), 
the cytotoxic T cell precursor (CTLp) assays and HLA antibody screening have shown to 
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be useful for monitoring transplant recipients, we question in this review the reliability of 
assays used so far for the detection of indirect allorecognition in clinical transplantation. 
ALLORECOGNITION AND ALLOGRAFT REJECTION 
Both the direct and indirect pathway of allorecognition can lead to graft rejection. Direct 
recognition of alloantigens predominates in the first weeks to months after transplanta-
tion and is generated by donor-derived antigen presenting cells bearing allogeneic MHC 
class II molecules. CD4+ T cells with exclusively direct allospecificity can mediate allograft 
rejection (4).
With elapsing time after transplantation, donor APCs fade away and the indirect pathway 
becomes more important. Evidence that the indirect pathway is sufficient to mediate graft 
rejection was provided by Auchincloss et al. (5), who used MHC class II deficient mice as 
donors in a skin allograft model. Indirect allorecognition of donor MHC class I antigens by 
host CD4+ T cells could initiate rapid skin rejection. Moreover, allospecific CD4+ T cells in-
duced by the indirect pathway were involved in the generation of cytotoxic T cells against 
donor MHC class I and the induction of IgG alloantibody production (5, 6). The availability 
of knock out mice and depletion of specific cell subsets enabled the study of individual cell 
types involved in indirect allorecognition. Combined with results from other experimental 
studies (2, 7-13), this provides circumstantial evidence that T cells exclusively activated by 
the indirect pathway are able to mediate acute and chronic allograft rejection. 
Many clinical studies in humans support the notion that an increased frequency or re-
activity of T cells with indirect anti-donor allospecificity is associated with chronic graft 
dysfunction or rejection. 
INDIRECT ALLORECOGNITION AND TRANSPLANTATION TOLERANCE
Indirect allorecognition can occur throughout the lifetime of a graft, since recipient APCs 
continuously migrate through the graft and encounter donor-derived peptides. Graft re-
jection can be caused by indirect allorecognition. However, a protective role of T cells with 
indirect allospecificity is also likely, as the presence of regulatory T cells with indirect al-
lospecificity is associated with transplantation tolerance. Immunological tolerance involves 
central and peripheral mechanisms (14). An example of the role of indirect allorecognition 
in inducing a state of central tolerance is the prolongation of graft survival after intrathy-
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mic administration of donor MHC peptides in rodents (15, 16). In the periphery, tolerance 
can be achieved by various mechanisms, including deletion and regulation of effector cells. 
Several studies described a state of peripheral tolerance caused by indirect allorecognition 
in presence of suboptimal stimulation (17-19), negative feedback (20) or regulation (21-24). 
It is also believed that the beneficial effect of pre-transplant blood transfusions (25-28) is 
mediated by regulatory T cells with indirect allospecificity (29, 30). 
Considering the central role of indirect recognition in graft rejection and tolerance, the 
availability of a reliable in vitro assay for monitoring indirect allorecognition is crucial.
IN VITRO ASSAYS TO MONITOR INDIRECT ALLORECOGNITION 
Studies that have established key factors for measuring indirect allorecognition in vitro are 
listed in Table 1. They show that in vitro allogeneic T cell responses require the presence 
of APCs, and that CD4+ cells recognize an allogeneic peptide in the context of a self-HLA 
class II molecule (31, 32). T cells described to respond to allogeneic peptides via the in-
direct pathway recognized synthetic HLA peptides, as well as endogenous peptides (33). 
Moreover, autologous dendritic cells (DCs) pulsed with cellular fragments were able to 
trigger T cells with indirect allospecificity (34, 35). Dominant epitopes on common HLA 
molecules were not limited to the hypervariable region of the HLA molecule, but could 
also be derived from the α3 and the transmembrane domains (36). Quantitative analysis 
showed that T cells with indirect allospecificity have a significantly lower frequency than 
cells involved in the direct allorecognition pathway (3) and could react by both prolifera-
tion and cytolysis (37). 
As chronic allograft rejection is thought to be mediated mainly by recipient T cells with 
indirect allospecificity, most in vitro assays aiming to detect indirect allorecognition have 
been performed after solid organ transplantation. As depicted in Table 2, recipient T cell 
reactivity to donor-like or donor-derived antigens was associated with acute as well as 
chronic rejection in numerous studies, except for some (38-43). However, in the following 
sections it will become evident that test conditions vary considerably among studies, while 
often essential controls are lacking. The different problems will be discussed, supported 
by our own in vitro experiments in order to underline the need to develop a robust and 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SOURCE OF ALLOANTIGEN 
Indirect allorecognition refers to the recognition of a foreign peptide in the context of an 
HLA class II molecule on self APCs by recipient CD4+ cells. The shedding of soluble HLA 
molecules during homeostasis or attack on graft tissue during inflammatory processes 
or other pathological conditions in vivo will lead to presence of allogeneic cells or cel-
lular fragments for presentation to the recipients’ immune system. They may end up in 
APCs, transported to the lymph nodes and presented to recipient T cells via the indirect 
pathway. The strength of this type of alloimmune response is dependent on the amount 
and source of antigen as well as on the strength and duration of the interaction between 
recipient APC and T cell. To ensure proper investigation of indirect alloimmune responses, 
the selection of alloantigens is crucial. Alloantigen can be derived from any polymorphic 
protein present in the donor and not in the recipient, but in the transplantation setting 
donor HLA molecules, which can be presented via the direct and indirect way, account 
for the vigorous alloimmune response. As alloantigen source, one can use donor cells or 
cellular fragments with the advantage that all possible alloantigens are available for indirect 
presentation. Alternatively, peptides from alloantigens can be generated synthetically for 
use in in vitro assays. The advantages and disadvantages of different sources of alloantigens 
will be discussed in more detail.
Allogeneic cells depleted of APCs
Theoretically, depletion of allogeneic APCs will prevent the response of recipient CD4+ T 
cells towards foreign HLA class II molecules, referred to as the direct way of allorecogni-
tion. As shown in Table 2a, the stimulation of recipient CD4+ T cells with APC-depleted 
allogeneic peripheral blood mononuclear cells (PBMC) correlated with acute rejection 
in two studies (44, 45), whereas other studies found no correlation between indirect al-
lorecognition and acute allograft rejection (39, 41, 46). However, it cannot be ruled out 
that direct allorecognition still interferes in the immune reaction as small numbers of 
residual donor APCs may remain present. Therefore, the use of cellular fragments lack-
ing intact HLA molecules seems to be a more safe way of alloantigen delivery for indirect 
recognition. 
Cellular fragments 
A big advantage of the use of fragments derived from cells of the organ donor is that theo-
retically the full repertoire of alloantigens is covered. After natural processing, peptides 
derived from the HLA class I and class II molecules but also from other (minor) transplan-
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tation antigens are presented by the recipients’ antigen presenting cells. A disadvantage 
is that the specificity of the alloreactive T cells is not known. Many different techniques 
have been used for the fragmentation of cells, which makes it difficult to compare results 
obtained by different studies. Nevertheless, all studies listed in Table 2b found a positive 
association between patient response to donor derived cellular fragments and acute or 
chronic allograft rejection (47-52). However, it should be noted that not all studies in-
cluded proper negative controls such as third party cellular fragments. 
Fragmentation of cells or cell membranes has some pitfalls. First, without further analysis, 
the content of a suspension after fragmentation is unknown with respect to the size of 
the particles. The suspension may contain whole membrane-derived HLA molecules or 
much smaller components similar in size to the synthetic peptides used in other experi-
mental designs. Few studies performed Western blot analysis or ELISA to demonstrate 
the presence of HLA molecules after fragmentation, but even then it is unknown whether 
the HLA molecules need to be intact in order to be processed and presented by an APC 
(48,51). When membrane fragments still contain intact HLA molecules and costimulatory 
molecules, these can cause allorecognition via the direct pathway by patient responder 
cells. Recipient APCs may also acquire and integrate intact donor-derived HLA molecules, 
a process called trogocytosis (53). Thus, the absence of cells in the preparation does not 
warrant absence of direct allorecognition. Second, the concentration of relevant con-
stituents is unknown. A wide range of cellular fragments was used (equivalents of 5×104 
to 2×106 cells), compared to the final concentration of synthetic peptides (10-20 µg/ml 
per synthetic peptide) used in most studies. The concentration of relevant peptides in a 
fragmented cell preparation is not known and may be much lower compared to the con-
centrations usually applied for synthetic peptides. 
The availability of many different protocols for fragmentation of cells to obtain donor-
derived antigens, underscores the lack of consensus on a robust and reliable test system.
To further illustrate this, we tested the reactivity of two CD4+ T cell clones against APCs 
with the specific restriction element after incubation with different preparations of the 
cellular fragments. Clone 4.1 recognizes an HLA-A2 peptide in the context of HLA-DR1. 
Clone 2014, derived from the ThoU6 cell line (33), recognizes an HLA-DR3 peptide in the 
context of HLA-DP3. Fragmentation of HLA-A2+ and HLA-DR3+ cells was performed 
using methods described by various studies (overview in Table 3). The reactivity of the 
clones towards natural ligand, synthetic peptides and cellular fragments was determined 
in proliferation and ELISPOT assays. Both clone 4.1 and clone 2014 recognized the natural 
ligand and the specific synthetic peptide but none of the cellular fragments (Figure 1). 
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To exclude that the lack of proliferation of the T cell clones was due to fragmentation in-
duced toxicity, T cell clones and the specific allopeptide were cultured with (supernatants 
of) cellular fragments. Fragmentation did not result in inhibitory or toxic substances and 
the response to the specific peptide remained intact (data not shown). 
Synthetic peptides
The studies presented in Table 2c used overlapping, synthetic peptides as source of donor 
antigen (36, 38, 40, 42, 43, 54-69). Both HLA class I and class II peptides corresponding to 
the donor phenotype, were used to stimulate patient cells. However, it can be assumed 
that donor-HLA class I-derived peptides are the major inducers of recipient T cell activa-
tion leading to chronic allograft rejection, since the expression of HLA class I molecules in 
the graft is far more abundant than that of HLA class II, especially after donor passenger 
cells bearing HLA class II molecules have disappeared. In that perspective, it is odd that 
several studies aim at the detection of a T cell response to synthetic HLA-DR peptides 
rather than to HLA class I peptides (54-63, 67). 
The advantage of using synthetic peptides is the exact knowledge of the antigen (amino 
acid length and concentration), resulting in a reproducible assay. By varying the amino acid 
length, immunodominant epitopes were identified for several HLA antigens. However, 
the indiscriminate dissection of a protein into synthetic peptides has disadvantages, one 
of them being the creation of new epitopes (neo-epitopes). Peptides may be synthesized 
which do not occur in vivo, due to absence of natural splicing sites at relevant positions on 
the full protein. On the other hand, when working from the encoded sequence, one does 
not take into account that several posttranslational modification mechanisms can occur in 
vivo. This includes glycosylation of proteins to improve protein folding and stability of the 
peptide-HLA complex (70). By exogenously offering 15- to 30-mer synthetic peptides to 
recipient APCs, they may end up directly in an HLA molecule in unglycosylated form. In 
addition, posttranslational splicing of peptides has been shown to occur (71). In peptide 
synthesis that is purely based on amino acid sequence of the full protein the latter two pos-
sibilities are simply not considered. Apart from this, and more importantly, a major flaw in 
many studies is the lack of appropriate peptide controls. To support the results of indirect 
T cell activation studies, inclusion of control peptides based on self-HLA sequences, seems 
to be a logical corollary, but is rarely performed.
Half of the studies used only peptides corresponding to the donor phenotype and based 
their conclusive remarks on the response to the specific peptide. These studies should be 
considered non-conclusive as responses to synthetic peptides corresponding to self-HLA 
molecules do occur frequently. Since the adaptive antigen-specific immune system distin-
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guishes self from non-self, starting with deletion of T cells in the thymus with a high affinity 
for self-antigens, it is not likely that individuals recognize a natural self peptide presented 
in the context of their own HLA class II. Figure 2 shows that reactivity was observed to 
synthetic peptides based on self-HLA molecules using cells from a healthy non-primed 
individual or umbilical cord blood (UCB). The peptides used here probably differ from 
naturally processed peptides and are seen as neo-epitopes by the autologous T cells. A 
logical consequence is that in some cases the reactivity towards synthetic allopeptides 
is interpreted incorrectly. This type of reactivity is not restricted to T cell responses to 
synthetic HLA peptides but also accounts for responses towards synthetic RhD peptides 
in RhD-positive individuals, as tested in our laboratory (data not shown). Our observa-
tions are in agreement with others. Hanvesakul et al. showed recognition of peptides with 
a sequence identical to self in patients awaiting a renal transplant, as determined in IFN-γ 
ELISPOT assay (36). Barker et al. described proliferation of naïve T cells of RhD-positive 
individuals to synthetic RhD peptides and concluded that this was presumably due to cor-
Table 3. Overview of different methods to fragment cells.
Fragmentation method
PBMC
1 (47,50) 2 3 (48,51) 4a SALs































1st centrifugation step – 20 min, 16,000 g,
RT
2 min, 1000 g,
4°C
2 min, 2000 g,
4°C
–
Sample Whole solution Supernatant Supernatant Supernatant Whole solutionc
2nd centrifugation step – – 45 min 14,000 g,
RT
2 min, 3000 g,
4°C
–
Sample – – Pellet Supernatant –
3rd centrifugation step – – – 60 min, 100.000 g,
4°C
–
Sample – – – Pellet –
aPersonal communication Dr. Maria Hernandez-Fuentes, King’s College London, UK.
bFreezing/thawing cycle in liquid nitrogen and waterbath, respectively.
cBefore use, cell suspension was filtered to remove cloths.
EDTA: ethylenediaminetetraacetic acid, PBMC: peripheral blood mononuclear cells, PMSF: phenylmethylsulphonyl 
fluoride, RT: room temperature, SALs: single antigen cell lines, SBTI: soybean trypsin inhibitor.
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respondence of the peptides to cryptic epitopes normally not presented in vivo (72). Two 
other studies also demonstrated that non-primed T cells are able to respond to alloge-
neic synthetic peptides (40, 42). Two possibilities arise for the response to self: absence 
of regulatory mechanisms or induction of neo-epitopes. Natural regulatory mechanisms, 
which prevent occurrence of an autoimmune response in vivo, may be absent in in vitro test 
systems. A more plausible explanation lies in the synthetic character of the peptides. A 
synthetic peptide does not use the normal route of processing and may end up as a new 
amino acid sequence in an HLA molecule of an APC. Responder T cells will recognize such 
Figure 1. Response of Clone 4.1 (panel a) and Clone 2014 (panel b) towards natural ligand, synthetic peptides and cel-
lular fragments. Clone 4.1 (recognizes HLA-A2 in HLA-DR1) proliferated upon stimulation with natural ligand (A2+DR1+ 
cell) or specific A2+ peptide (aa 101-122), but not upon stimulation with A2+ or A2- cellular fragments, produced by 
method 1, 2, 3 or 4 (n=3). Clone 2014 (recognizes HLA-DR in HLA-DP3) produced IFN-γ as measured in ELISPOT upon 
stimulation with natural ligand (DR3+DP3+ cell) or specific DR3+ peptide (U6), but not upon stimulation with DR3+ or 
DR3- cellular fragments, produced by method 1, 2, 3 or 4 (n=2). Stimulation index panel a: counts per minute (CPM) of 
stimulated clone divided by CPM of unstimulated clone (medium control). Stimulation index panel b: IFN-γ production of 
stimulated clone divided by IFN-γ production of unstimulated clone (medium control). 
a new epitope (neo-epitope) in the context of self HLA class II; however this type of rec-
ognition is not necessarily related to indirect recognition of a naturally processed allopep-
tide. To our opinion, positive tests obtained with synthetic peptides should be confirmed 





Besides the antigenic stimulus, the responder cell population, as well as the experimental 
setup of an in vitro assay, are crucial. The optimal location to detect recipient T cells with 
indirect allospecificity would be in or near the graft, since T cells migrate towards the graft 
after they have been triggered by recipient APCs presenting a donor derived peptide. In 
the graft they are supposed to exert their effector functions, which eventually may cause 
graft rejection. Although the frequency of T cells with indirect allospecificity during rejec-
tion may be 10-50 fold higher in the graft than in the periphery (54), for practical reasons 
most studies have been performed with PBMC.
Figure 2. Proliferative response (in triplicate) of healthy control PBMC (panel a) and umbilical cord blood (UCB; panel 
b) towards foreign synthetic peptides (HLA-A1 and HLA-A2 respectively) and peptides corresponding to self (HLA-A2 
and HLA-B7 respectively). HLA type of healthy control: A2, A25, B7, B18, Cw4, Cw12, DR1, DR15, DQ5, DQ6. HLA type 
of UCB: A3, A32, B7, B35, Cw4, Cw7, DR11, DR15, DQ3, DQ6. Peptides were added in pools of 3 overlapping 30-mer 
peptides. Proliferation was measured at day 7. MRM: memory recall mix. Stimulation index: counts per minute (CPM) of 
stimulated cells divided by CPM of unstimulated cells (medium control).
In some studies donor antigens were added to PBMC, by which the encounter of antigen, 
processing and presentation by autologous APCs occured in the same environment as 
presentation to T cells. Only a few studies used a more sophisticated system, in which 
autologous APCs were purified by T cell depletion, incubation with antigen and finally 
added to responder T cells (42, 47, 49). To refine the antigen presenting cell population, we 
performed costaining experiments of fragments of single antigens lines (SALs) and differ-
ent cell populations (Figure 3). Only CD14+ cells (monocytes) showed costaining of PKH26 
(a) (b)
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labeled SAL fragments and may be able to internalize the fragments, process them and 
finally present them in the context of HLA class II. This allows for selection of the proper 
APC population and control the ratio between CD14+ APCs and T cells. In order to de-
velop and validate a reliable in vitro system, standardization and quality controls within the 
different phases leading to indirect allorecognition are inevitable. 
As read out, most studies focused on the capacity of CD4+ cells to proliferate upon stimu-
lation, but differ in other test characteristics. Proliferative capacity is often measured upon 
coculture with synthetic peptides or cell fragments directly or after stimulation in limiting 
dilution analysis (LDA). LDA quantifies the response by measuring the frequency of allo-
reactive cells, but involves prolonged in vitro culture systems, which may affect estimations 
of the true in vivo frequencies. More recently, ELISPOT and flow cytometric approaches 
are used to estimate the number and phenotype of alloreactive T cells respectively. The 
ELISPOT is more sensitive than other techniques, such as MLC and ELISA, but represents 
a snapshot of the T cell response. Some of the cytokine-producing cells may not proceed 
Figure 3. Costaining of SAL fragments on different cell populations. SAL fragments (stained with PKH26) were incu-
bated for various lenghts of time with PBMC (stained for different cell populations) (n=2). The percentage of double 
stained cells was determined in flowcytometric analysis. 
to proliferation or may undergo activation-induced cell death (68). The flow cytometric 
approach allows for the individual characterization of cells and the subsequent staining 
for cytokines to refine the categorization of specific cell subsets, rather than just surface 
markers. Because a major feature of T cells with indirect allospecificity is their low fre-
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quency, a sensitive technique is required. In this respect, the phenotypic characterization 
of alloreactive T cells has an additional benefit above standard proliferation assays.
When monitoring patients, it is essential to distinguish the response of naïve cells from 
that of primed donor reactive T cells. To develop an in vitro assay able to detect T cells 
with primed indirect allospecificity, one should focus on the detection of memory cells. 
Therefore, knowledge about the kinetics of a response is crucial. In our above-described 
experiment using stained SAL fragments cocultured with stained PBMC, it was possible 
to monitor the double positive-stained cells at different time points (Figure 3). Within 24 
h after coculture, 25% of the CD14+ cells showed costaining of SAL fragments. This time 
span is in agreement with results of a recently performed study in which a time period 
of 16-20 h was found to be necessary for processing, intracellular routing and peptide 
presentation by APCs (34). Considering the use of primed responder cells and the uptake 
and processing of antigen within 1 day, one may question the need for a 7 day incubation 
period to detect memory cells as is used in most studies. Because cytokine secretion pre-
cedes proliferation upon stimulation, incubation of recipient PBMC with donor antigens 
in ELISPOT was usually much shorter. Nevertheless, a study focusing on the kinetics of a 
memory is required to shed light on this. 
CONCLUDING REMARKS
Various studies claim a relationship between the reactivity of T cells with indirect allo-
specificity and graft rejection. However, many different approaches are used and often, es-
sential controls are lacking. Hardly any study confirms the presence of indirect recognition 
using different approaches including the natural ligand. This is essential as all assays used so 
far clearly have disadvantages and pitfalls. 
The use of donor cells for fragmentation has our preference as antigen source for in vitro 
assays because they contain the full HLA phenotype. However, no method to fragment 
cells has emerged as optimal, which is emphasized by the lack of consensus. Addition-
ally, one should include control experiments when using fragmented cells to exclude rec-
ognition of alloantigens via the direct pathway. The exact knowledge of the alloantigen 
when using synthetic peptides is overshadowed by the ability to create neo-epitopes. This 
turned out to be a big obstacle in defining a specific response and requires at least the 
use of control peptides. Besides different antigenic sources, additional differences exist 
in test characteristics between studies in which most of them do not distinguish a naïve 
response from a memory response. To monitor the low frequency of T cells with indirect 
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allospecificity in vitro, it is essential to determine the kinetics and optimal conditions to 
detect a memory response. 
Detailed knowledge about the indirect allorecognition is required and it would be the right 
time to set up an international workshop to establish and validate a proper and robust 
assay to measure T cells with indirect allospecificity. 
MATERIALS AND METHODS
Subjects and sample collection
PBMC from heparinized peripheral blood from healthy individuals or mononuclear cells 
from umbilical cord blood (UCB) were isolated by standard Ficoll density-gradient centrif-
ugation. PBMC were used immediately as responder cells in proliferation assays or were 
cryopreserved in RPMI 1640 (Gibco, Paisley, UK) with 20% fetal calf serum (FCS, Gibco) 
and 10% dimethyl sulfoxid (DMSO, Fluka, Buchs, Switzerland). Cells were frozen at -70°C 
and stored in liquid nitrogen until further use. 
T cell clones
The T cell line ThoU6 was obtained as described before (33). In brief, PBMC of individual 
Tho (DPB1*0301+, DRB1*0301-) were primed in the presence of an HLA-DR3 peptide 
(aa 67-85: LLEQKRGRVDNYCRHNYGV) in RPMI 1640 supplemented with 15% pooled 
human serum and gentamycin. After 7 days, the cultures were collected and restimulated 
with irradiated autologous feeder cells at a ratio of 10:1 and synthetic HLA-DR3 peptide. 
The line was cloned by limiting dilution in the presence of T cell growth factor (TCGF, 
Biotest, Germany) and irradiated autologous feeder cells. The CD4+ clone 2014 was kept 
in culture by weekly stimulation with irradiated allogeneic PBMC with IL-2 in RPMI 1640 
supplemented with 10% pooled human serum. 
The CD4+ T cell clone 4.1 recognizes an HLA-A2 peptide (aa 101-122: CDVGSDWRFLR-
GYHQYAYDGKD) presented in HLA-DR1. The clone was maintained in culture by weekly 
stimulation with irradiated allogeneic PBMC and allogeneic B cells, PHA and IL-2 in IMDM 
(Gibco) with 10% pooled human serum. Both T cell clones were used in functional assays 
between 1 and 2 weeks after restimulation. 
Synthetic peptides
Synthetic 20-mer overlapping peptides corresponding to residues 45-66 and 101-122 of α1 
and α2 domain from HLA-A2 alleles and synthetic 30-mer overlapping peptides represent-
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ing the α1 and α2 domain of HLA-A1, -A2, -B7 and -B8 were synthesized by solid-phase 
strategies on an automated multiple peptide synthesizer (Syro II; MultiSynTech, Witten, 
Germany). The purity of the peptides was determined by analytical reversed-phase high 
performance liquid chromatography (HPLC).
Cellular fragments
Fresh or thawed PBMC or SALs were used for fragment preparation. Fragmentation of 
PBMC was performed using 4 different methods:
• Method 1: PBMC were lysed by three cycles of freezing (liquid N2) and thawing (water-
bath: 37°C) in RPMI 1640 complete medium at a concentration of 2×107 cells/ml. The 
absence of whole intact cells was confirmed by microscopy (47, 50). 
• Method 2: PBMC were lysed by three cycles of freezing (liquid N2) and thawing (wa-
terbath: 37°C) in RPMI 1640 complete medium at a concentration of 2×107 cells/ml, 
centrifuged at 16.000 g for 20 min and the supernatant was collected. 
• Method 3: PBMC were lysed by three cycles of freezing (liquid N2) and thawing (wa-
terbath: 37°C) in a Tris-EDTA-based buffer containing 1/5000 NP-40 (Fluka, 74385), 
0.1mM PMSF (Sigma P7626; Buchs, Switserland), 1/200 protease inhibitor mixture 
(Sigma, P8340) and 5 ng/ml soybean trypsin inhibitor (Sigma, T6522), centrifuged at 
1000 g for 2 min, and the supernatant was collected and further centrifuged at 14.000 
g for 45 min at 4°C (48, 51). 
• Method 4: PBMC were lysed by three cycles of freezing (liquid N2) and thawing (wa-
terbath: 37°C) in a Tris-EDTA-based buffer containing 1/8000 NP-40 (Fluka, 74385), 
0.1mM phenylmethanesulfonyl fluoride (PMSF, P7626, Sigma, Buchs, Switserland), 
1/800 protease inhibitor mixture (Sigma, 8340) and 5 µg/ml soybean trypsin inhibitor 
(Sigma, T6522), centrifuged at 2000 g for 2 min (4°C), followed by a centrifugation step 
of the supernatant at 3000 g for 2 min (4°C). Supernatant was harvested and further 
centrifuged at 100.000 g for 60 min (4°C) in the buffer described above. The pellet 
was resuspended in 10-20 µl of solubilising solution: urea (Sigma, U0631), 2% CHAPS 
(Calbiochem, San Diego, CA, USA) and protease inhibitor cocktail (Roche 1836153; 
Basel, Switserland) (personal communication Dr. Maria Hernandez-Fuentes, King’s 
College London, UK).
Fragmentation preparations were tested for protein concentrations using BCA protein 
assay kit (Pierce, Rockford, IL, USA) and stored at -70°C until further use.
Fragmentation of SALs was similar to method 1, but one additional round of freeze/thaw-
ing was performed. Before use, the cell suspension was filtrated through a 70 µm cell 
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strainer (Falcon; BD Bioscience, Bedford, MA, USA) to remove cell cloths. 
Proliferation assays: healthy control and UCB 
A total of 2×105 PBMC of healthy individuals or mononuclear UCB cells were incubated 
with a pool of three synthetic HLA-derived peptides at a final concentration of 10 µg/ml 
per peptide. As a positive control a memory recall mix (MRM) was used containing tetanus 
toxoid (SVM, Bilthoven, the Netherlands), mycobacterium tuberculosis sonicate (Statens 
Serum Institute, Copenhagen, Denmark) and Candida albicans (HAL Allergy, Haarlem, the 
Netherlands). The cells were plated out in round-bottom 96-well plates (Costar, Cam-
bridge, MA, USA) in a total volume of 200 µl of RPMI 1640 complete medium supple-
mented with 5% autologous serum. After 6 days, wells were pulsed with 1 µCi of 3H-TdR 
(Amersham International, Amersham, UK) and the cultures were harvested onto glass 
fiber filters 18 h later. Proliferation was measured by 3H-TdR incorporation using a beta-
plate counter (Wallac, Turku, Finland). 
Proliferation assay: clone 4.1
A total of 105 irradiated (30 Gy) A2-DR1+ PBMC were pulsed overnight with A2+ synthetic 
peptides at a final concentration of 10 µg/ml per peptide or A2+/- cellular fragments at a 
final concentration of 1µg/well in IMDM complete medium with 5% pooled human serum. 
Also, intact A2-DR1+, A2+DR1+ or A2-DR1- cells were kept overnight in Iscove ś medium. 
T cell clone 4.1, which was kept overnight at 37°C in Iscove’s medium containing 100 U/ml 
IL-2, was then added at 5×103 cells per well. After 48 h, wells were pulsed with 1 µCi of 
3H-TdR and proliferation was measured as described above. 
Enzyme linked immunospot (ELISPOT) assay: clone 2014
A total of 105 irradiated (30 Gy) DR3-DP3+ PBMC were pulsed overnight with DR3+ syn-
thetic peptides at a final concentration of 10 µg/ml per peptide or cellular fragments at a 
final concentration of 1 µg/well IMDM with 5% pooled human serum. T cell clone 2014, 
which was kept overnight at 37°C in Iscove’s medium containing 20 U/ml IL-2, was then 
added at 5×103 cells per well, centrifuged for a short time to concentrate the cells and 
stored for 2 h at 37°C. Then, cells were harvested and transferred to an ELISPOT plate 
(MAHA S45 10, Millipore, Amsterdam, the Netherlands) coated with a mouse anti-human 
IFN-γ mAb (Mab 1-D1K; Mabtech, Nacka, Sweden) followed by blocking for 1 h at 37°C 
with RPMI 1640 containing 5% pooled human serum. Cells were incubated in the ELISPOT 
plate for 24 hr at 4°C to allow spot formation. Plates were washed with PBS supplement-
ed with Tween20 and an IFN-γ detection antibody (Mab 7-B6-1-biotin; Mabtech, Nacka, 
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Sweden) was added for 2 h at room temperature (RT). The conjugate (extravidin alkalin 
phosphatase, Sigma E2636) was added for 1 h at RT, followed by a washing step and addi-
tion of the substrate (BCIP-NBT tablet, Sigma B5655) for 5 min at RT. The reaction was 
stopped with tap water. The resulting spots were counted using a Bioreader 3000 Pro 
(BioSys, Karben, Germany).
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SUMMARY AND GENERAL DISCUSSION
Organ transplantation is a life saving procedure for many end-stage diseases. Generally, 
short-term transplantation outcome is excellent, mainly due to progress that has been 
made within the last 50 years. The discovery of HLA in the late 1950s (1-3) has allowed for 
the development of tissue typing techniques to ensure the best possible match between 
donor and recipient (4). Particularly in the era where powerful immunosuppressive drugs 
were not yet available, the impact of matching for HLA proved to be highly significant (5), 
and facilitated the establishment of clinical organ transplantation.
Introduction, in the late 1960s, of the serologic cross-match technique for the detection of 
pre-transplant donor specific antibodies has had tremendous impact on short term graft 
survival, since hyper-acute rejection could now be prevented (6). The serologic cross-
match technique involves in vitro incubation of donor cells and patient serum to screen for 
pre-existent humoral immune reactivity towards the graft in vivo. A positive cross-match 
remains to this day, at least in most European transplant centers, a contra-indication for 
transplantation.
Finally, the introduction of the potent immunosuppressive drug cyclosporin in the early 
1980s was instrumental for the prevention of acute rejection (7) and opened a new era in 
organ transplantation in which the discovery and development of new immunosuppressive 
drugs became an important field of investigation.
In contrast to the vast improvement of one-year graft survival rates in the last decades, 
long-term graft survival rates have made little progress (8). For the most part this is due 
to chronic organ failure, a multifactorial process caused by both immunological and non-
immunological damage to the graft (9). Distinct from acute rejection, the immunological 
damage resulting in chronic graft failure affects the transplanted organ in a slow, continu-
ous fashion and appears to be relatively insensitive to current immunosuppressive drugs 
(10). It is important to understand the mechanism of the chronic rejection process to 
be able to interfere with it. The humoral immune response appears to be a major fac-
tor contributing to chronic rejection, since development of anti-HLA antibodies regularly 
precedes chronic rejection (11-13) and C4d staining revealed a strong correlation between 
chronic rejection and humoral immunity (14).
Maintenance immunosuppressive drugs
Since the majority of immunosuppressive drugs do not specifically target the humoral im-
mune system, humoral rejection episodes have proven to be difficult to treat, leading to a 
significantly reduced long-term graft survival (15). Nonetheless, maintenance immunosup-
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pressive drugs are likely to have an effect on B cells due to similarities between activation 
pathways of lymphocyte subsets (16). Moreover, inhibition of T cell help may lead to a di-
minished humoral allo-immune reactivity. Therefore, the composition of the maintenance 
immunosuppressive regimen may affect the susceptibility to, and outcome of, humoral 
rejection episodes.
We studied the direct effect of four immunosuppressive drugs, widely used as mainte-
nance immunosuppressive therapy (tacrolimus, cyclosporin, MPA and rapamycin), on in 
vitro humoral immune responses in great detail. Data presented in chapter 2 show that 
not all immunosuppressive drugs are equally capable of directly inhibiting B cell responses. 
Purified B cells were polyclonally activated with stimuli of various strength. MPA and ra-
pamycin completely inhibited immunoglobulin production, even after strong B cell stimu-
lation, in contrast to the calcineurin inhibotors cyclosporin and tacrolimus, whose effect 
was only marginal and dependent on the strength of B cell activation. Addition of MPA 
and rapamycin to already activated B cells resulted in strongly decreased immunoglobulin 
levels, whereas calcineurin inhibitors were ineffective at this stage. MPA and rapamycin 
inhibited B cell proliferation and induced B cell apoptosis. Moreover, rapamycin inhibited 
the number of IgM and IgG producing cells. From this chapter, we conclude that MPA and 
rapamycin are superior in directly inhibiting B cell responses, and may therefore be pre-
ferred to treat humoral rejection.
To establish whether calcineurin inhibitors can inhibit humoral immune responses indi-
rectly, we investigated their effect on T cell help. Chapter 3 describes the effect of 
tacrolimus, cyclosporin, MPA and rapamycin on various aspects of T cell help as well as 
in vitro humoral immune responses consisting of B cells stimulated by helper T cells. To 
address the effect of immunosuppressive drugs on T cell help, we polyclonally activated T 
cells in the absence and presence of immunosuppressive drugs and measured proliferation, 
expression of general T cell activation markers, as well as T cell help in the form of costim-
ulation and cytokines. Calcineurin inhibitors mainly affected the levels of T cell costimula-
tory molecule expression and cytokines, whereas MPA and rapamycin strongly inhibited 
T cell proliferation in addition to the attenuation of costimulatory molecule expression. 
Rapamycin affected the production of multiple B cell stimulatory cytokines, whereas MPA 
did not affect cytokines. Subsequently, in T cell dependent B cell cultures, all immunosup-
pressive drugs tested were capable of completely inhibiting immunoglobulin production. 
From these data we conclude that all immunosuppressive drugs are capable of inhibiting T 
cell help, albeit to different extents. We confirmed that calcineurin inhibitors affect B cell 
immunoglobulin production by interfering with T cell help in a culture system using already 
activated T cells to stimulate B cells.
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Since the relative contributions of T cell proliferation, costimulation and cytokines to B 
cell activation in this culture system are not known, we are unable to conclude that one 
of the drugs is superior in inhibiting T cell help towards B cells. Nonetheless, among the 
drugs we have tested, rapamycin had the broadest range of effects on T cell help, suggest-
ing that this drug is most potent in inhibiting T cell dependent B cell responses. Figure 1 
provides a simplified overview of the action of the immunosuppressive drugs described in 
this thesis.
It is highly unlikely that the problem of humoral rejection will be solved using the current 
standard immunosuppressive drugs. However, until an effective therapy becomes available, 
the impact of standard immunosuppressive drugs on humoral immunity remains impor-
tant. Based on our data, we hypothesize that the choice of immunosuppressive drugs in-
cluded in the maintenance immunosuppressive protocol affects the propensity of a patient 
to develop humoral rejection and may also determine the outcome of the rejection. From 
our data, it is evident that MPA and, even more clearly, rapamycin are superior in inhibiting 
humoral immune responses, and thus may be the drugs of choice in maintenance immuno-
suppressive protocols.
Experimental immunosuppressive protocols
In addition to standard immunosuppressive drugs, many experimental immunosuppres-
sive protocols are used in efforts to treat humoral rejection, including high dose IVIg, 
Rituximab and plasmapheresis (17-19), as well as bortezomib (20, 21). IVIg has been widely 
used for treatment of humoral immunodeficiency and autoimmune diseases, and its use 
in transplantation is on the rise. However, the mechanism of action of IVIg, especially in 
the setting of organ transplantation, has not been fully elucidated. Therefore, in studies 
described in chapter 4, we questioned whether IVIg affected the activation of highly pu-
rified B cells. We stimulated B cells with recombinant stimulatory agents, resulting in the 
induction of proliferation and immunoglobulin production. Unexpectedly, we found that 
IVIg (in concentrations up to 35 mg/ml) failed to affect B cell proliferation. In contrast, IVIg 
did inhibit the proliferation of mitogen activated T cells, warranting that the IVIg solution 
was effective. Additionally, we tested whether IVIg altered immunoglobulin production by 
addressing the mRNA levels of IgM and IgG. Similar to the lack of effects on B cell prolif-
eration, IVIg did not alter immunoglobulin mRNA levels.
Since IVIg has been described to inhibit humoral immune responses in vivo, we hypoth-
esize that IVIg interferes with T cell help. This hypothesis is supported by our data on 
IVIg-induced inhibition of mitogen-induced T cell proliferation, as well as data from others 
showing inhibition of T cell activation and proliferation by IVIg (22, 23). Besides effects of 
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IVIg on cells involved in humoral immune responses, IVIg may also influence humoral im-
mune responses by interfering with the complement system (24, 25), or by anti-idiotypic 
interactions with pathogenic antibodies (26). However, the contribution of these mecha-
nisms to the inhibition of humoral allo-immunity remains unknown and requires further 
investigation.
To be able to address the question whether IVIg has an effect on humoral rejection, in vivo 
studies will be extremely informative. However, performing studies in which transplant 
patients are randomized between IVIg therapy and placebo will raise ethical concerns. 
On the other hand, testing the effect of a human plasma product on the immune system 
of laboratory animals will likely not provide relevant information for the human situation. 
Instead, the use of humanised mouse models, in which human tissues can be transplanted, 
may allow investigating the effect of IVIg on the human immune system in vivo. 


























Figure 1. Simplified scheme of the effects of immunosuppressive agents on T cell dependent B cell activation. The 
calcineurin inhibitors cyclosporin and tacrolimus potently inhibit T cell help towards B cells by interfering with T cell 
proliferation, cytokine production and costimulatory molecule expression, but lack direct effects on B cells. Both MPA 
and rapamycin inihibit T cell help towards B cells as well as B cell function directly. MPA and rapamycin inhibit T cell 
proliferation and costimulatory molecule expression, with rapamycin also inhibiting T cell cytokines. Both drugs inhibit B 
cell proliferation and induce B cell apoptosis. Additionally, rapamyin directly inhibits B cell antibody production. IVIg does 
not directly inhibit B cells when tested in a T cell free culture system. However, IVIg directly inhibits T cell proliferation 
by a mechanism yet to be determined. Bortezomib inhibits B cell proliferation and antibody production when tested in 
a culture system lacking T cells. We hypothesize that, in analogy with its effect on plasma cells, Bortezomib affects B 
cells by inhibition of the proteasome.
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To prevent development of novel HLA antibodies after transplantation, B cells can be 
depleted from the circulation. Since B cells are also potent in activating T cells by antigen 
presentation (27), an additional advantage of B cell depletion is the removal of this im-
portant source of antigen presenting cells. The commonly used chimeric anti-CD20 mAb 
Rituximab leads to profound B cell depletion, which lasts over 6 months (28). Several 
studies have shown beneficial effects of Rituximab on graft survival (18, 19), stressing the 
important role of B cells in rejection. In addition to Rituximab, novel B cell depletion strat-
egies are under investigation in the field of autoimmunity, such as anti-CD79 mAb, which 
ameliorates murine auto-immune disease (29) and epratuzumab (an anti-CD22 mAb), 
which, besides B cell depletion, affects B cell activation in SLE patients (30). 
Unfortunately, Rituximab treatment appears not to be effective in all instances, which is 
illustrated by reports on the failure of Rituximab to prevent humoral rejection (31, 32). 
Most likely, this is caused by ongoing antibody production by plasma cells. Bone marrow 
residing plasma cells are responsible for the preponderance of antibodies present in the 
circulation, but are not affected by Rituximab treatment, since they lack CD20 expres-
sion. This is evidenced by unaltered normal serum immunoglobulin concentrations during 
Rituximab induced B cell depletion (33). Alternative strategies, such as IVIg or ATG admin-
istration and plasmapheresis, also leave plasma cells unaffected (34, 35). Lack of inhibition 
of plasma cell activity presents a major impediment to the treatment of humoral rejection. 
Recently, the proteasome inhibitor bortezomib, originally designed for the treatment of 
multiple myeloma, has been described as an effective therapy for both humoral and cellular 
rejection in a study involving a small patient cohort (20). Additionally, HLA antibody levels 
in non-rejecting patients were attenuated (21). Immunosuppressive effects of bortezomib 
are caused by induction of plasma cell apoptosis (35). However, it is to be expected that 
induction of apoptosis by proteasome inhibition is a general effect on cells with high pro-
tein turnover. Therefore, we have investigated the effect of bortezomib on activated B 
cells, as described in chapter 5. Bortezomib potently inhibited B cell proliferation and 
immunoglobulin levels. The dose at which bortezomib exerted maximal effects was ap-
proximately a 1000-fold lower than described for plasma cells (35), suggesting that B cells 
are even more susceptible to the effect of bortezomib than plasma cells. The mechanism of 
action of bortezomib towards human B cells has yet to be defined, although it is likely that 
the effects are caused by the induction of apoptosis, analogous to plasma cells. Induction 
of B cell apoptosis has already been demonstrated in murine B cells (36).
Preliminary results on the use of bortezomib are promising. The finding that human B cells 
are affected by bortezomib suggests that the use of additional B cell specific drugs, such as 
Rituximab, may not be necessary. Monitoring of B cell numbers and subsets in transplant 
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patients receiving bortezomib therapy will provide more insight on whether B cells are 
sufficiently affected to make B cell specific therapy superfluous. 
However, due to the apparent lack of specificity, side effects may be expected. Large 
multicenter studies will be needed to determine whether bortezomib is truly the potent 
anti-humoral rejection drug it appears to be and what side effects can be expected in 
transplant patients.
Monitoring the immune system
Once an organ has been transplanted, monitoring of the alloimmune response is of great 
importance to tailor immunosuppressive drugs for the minimization of side effects. His-
torically, the humoral alloimmune response is monitored by quantification of the level of 
donor-specific serum antibodies. However, there are several reasons why the detection of 
serum alloantibodies may not be adequate. Firstly, alloantibodies may not be detected in 
the periphery because of antibody adsorption by the graft, as has been demonstrated by 
studies on serum alloantibody negative patients who experienced graft failure. In these pa-
tients, only after transplantectomy serum alloantibodies were detectable, indicating anti-
body adsorption by the graft (37, 38). Secondly, at the time that alloantibodies are detected 
in the circulation, the humoral immune response is already ongoing, and intervention is 
likely too late to prevent organ damage. Finally, when only antibody levels are measured, 
the proportion of the B cell clones capable of producing the alloantibodies or differentiat-
ing into plasma cells remains unknown.
To get around these problems, we developed a novel ELISPOT technique to quantify the 
number of B cells capable of producing IgG antibodies against defined HLA molecules. 
Development of this ELISPOT assay, which is described in chapter 6, was possible by 
using recombinant monomeric HLA molecules as target molecules for the HLA antibodies 
to bind. We determined the frequency of HLA antibody producing B cells of several HLA-
immunized individuals and found frequencies of 0 to 182 HLA-specific B cells per million 
B cells. In contrast, B cells from non-immunized controls and from individuals whose HLA 
type corresponded to the HLA of the test did not form spots. Moreover, we were able 
to detect HLA-specific B cells in a patient who had developed HLA antibodies due to al-
lograft rejection.
We hypothesize that the production of alloantibodies of certain specificity will be pre-
ceded by an increase of B cells clones of the same specificity. Therefore, by monitoring 
the frequency of HLA-specific B cells longitudinally, we may be able to detect a humoral 
allo-immune response in the early phase. Whether the increase of peripheral HLA-specific 
B cells will actually precede the formation of antibodies may be subject of future investiga-
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tions in which samples from transplant patients, who developed humoral rejection, will 
be retrospectively tested for their HLA-specific B cell load. Once these studies have been 
performed, the HLA-specific B cell ELISPOT may be added to the current repertoire of 
techniques to monitor transplant patients. 
The HLA-specific B cell ELISPOT may also be used to determine the effect of immunosup-
pressive drugs on HLA-specific B cells. However, the present culture method prior to the 
ELISPOT assay is based on artificial T cell help by irradiated L-CD40L cells. This precludes 
studies on the effect of immunosuppressive drugs on the frequency of HLA-specific B cells, 
since immunosuppressive drugs may act on L-CD40L cells. Further development of the 
assay to eliminate L-CD40L cells from the pre-culture may render the assay suitable for 
the investigation of immunosuppressive drugs.
The previously mentioned T cell help is pivotal for B cells to differentiate into memory B 
cells or IgG producing plasma cells. T cell help is, by definition, provided by CD4+ T cells. 
Early after transplantation, CD4+ T cells will predominantly recognize foreign HLA di-
rectly on the cell surface of donor DCs. In contrast, late after transplantation, when donor 
DCs are no longer present, CD4+ T cells will recognize allogeneic structures as peptides in 
the context of self-MHC, a pathway known as the indirect pathway of allorecognition. To 
be able to predict late transplant outcome and monitor the chronic alloimmune response, 
proper techniques are required to quantify T cells capable of indirectly recognizing donor 
HLA. Chapter 7 summarizes the current literature describing assays to quantify the 
indirect allo-recognition, accompanied by data from our own laboratory showing the pit-
falls of such techniques. Many papers cited in this chapter lack proper controls, rendering 
interpretation of the data extremely difficult. Our own data underscore the necessity of 
proper control samples and the difficulty to define and implement such controls. 
Selection of the source of alloantigen to test indirect alloreactivity is critical and potentially 
induces errors. A major problem in assays using cell lysates to detect alloreactivity is the 
inability to formally exclude any direct alloreactivity. Detailed analysis of cell lysates by, 
for example, mass-spectometry may be required to ensure no intact HLA molecules are 
present in the lysate, ruling out direct alloreactivity. Alternatively, when using synthetic 
peptides, the induction of reactivity against neo-epitopes cannot be excluded, which is a 
problem that is extremely difficult to overcome. Reactivity towards peptides should be 
validated by using other sources of antigen, which is seldomly done. We conclude from this 
systematic literature scan that, to date, there is no reliable assay to determine the human 
T cell repertoire with indirect allospecificity. However, development of reliable assays to 
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De natuurlijke afweer van het lichaam wordt verzorgd door het immuunsysteem. Zonder 
immuunsysteem zouden pathogenen zoals virussen en bacteriën vrij spel hebben. Het im-
muunsysteem is onder te verdelen in twee onderdelen, de aangeboren immuniteit en de 
verworven immuniteit. De aangeboren immuniteit bestaat onder andere uit fysieke bar-
rières zoals de huid en de slijmvliezen. Ook zijn er een aantal celtypen en moleculen die 
op een niet-specifieke manier (onderdelen) van pathogenen kunnen herkennen en deze 
kunnen neutraliseren. 
De verworven immuniteit wordt, zoals de naam al doet vermoeden, opgebouwd naarmate 
het lichaam in aanraking komt met pathogenen. Cellen uit deze tak van het immuunsys-
teem hebben specifieke receptoren op hun celoppervlak waarmee ze pathogenen kunnen 
herkennen. Deze cellen zijn ook in staat geheugen op te bouwen zodat bij een tweede 
aanval van hetzelfde pathogeen er sneller actie ondernomen kan worden. Het verworven 
immuunsysteem bestaat ruwweg uit twee celtypen; de T cellen die zorgen voor cellulaire 
immuniteit en de B cellen die zorgen voor de humorale immuniteit. Het cellulaire im-
muunsysteem surveilleert voor pathogenen binnenin cellen, waarbij geïnfecteerde cellen 
door T cellen opgeruimd worden. Lichaamsvreemde eiwitten worden hiervoor door de 
geïnfecteerde cel op speciale receptoren gepresenteerd. Het humorale immuunsysteem 
houdt de ruimte tussen cellen vrij van pathogenen, voornamelijk door het maken van anti-
stoffen. Dit zijn moleculen die binden aan pathogenen, welke vervolgens op verschillende 
manieren kunnen worden vernietigd. De twee armen van het verworven immuunsysteem 
zijn nauw met elkaar verbonden. Zo hebben de meeste B cellen T cellen nodig om volledig 
geactiveerd re raken, de zogenaamde T cel hulp, en kunnen B cellen T cel activatie bevor-
deren door lichaamsvreemde eiwitten aan T cellen aan te bieden.
Het immuunsysteem beschouwt een getransplanteerd orgaan als lichaamsvreemd (behalve 
wanneer het een orgaan van een ééneiige tweeling betreft) en zal daarom tot de aanval 
overgaan, wat kan leiden tot afstoting van het transplantaat. Afstoting van een getrans-
planteerd orgaan is dus eigenlijk een normale reactie van het lichaam op een ‘pathogeen’. 
Als niet de juiste selectiecriteria voor donoren en voorzorgsmaatregelen in de vorm van 
medicatie zouden worden genomen, zouden de meeste getransplanteerde organen door 
het immuunsysteem van de ontvanger worden afgestoten.
Sinds het begin van de orgaantransplantatie is door onderzoek grote vooruitgang geboekt 
op de korte termijn transplantaat overleving. Ten eerste is de ontdekking van weefsel 
groepen (de HLA moleculen), die bij ieder uniek individu verschillend zijn, zeer belangrijk 
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geweest voor het selecteren van de juiste donor. Deze ontdekking heeft de basis gevormd 
voor de weefseltypering. Zonder juiste medicatie veroorzaakt een verschil in de opmaak 
van HLA moleculen tussen donor en ontvanger vrijwel zeker afstoting van het getrans-
planteerde orgaan. 
Als tweede mijlpaal in de transplantatie immunologie is de ontwikkeling van de zogenaamde 
kruisproef van groot belang geweest om versnelde, hyperacute afstoting te voorkomen. 
Bij deze techniek wordt serum van de potentiële ontvanger in contact gebracht met cellen 
van de donor. Als de patiënt reeds antistoffen in het serum heeft die reageren tegen de do-
nor zullen in deze test de donorcellen vernietigd worden. Dergelijke antistoffen kunnen in 
de patiënt reeds aanwezig zijn door zwangerschap (bloed uitwisseling met het ongeboren 
kind), bloedtransfusies of eerdere transplantaties. Een positieve kruisproef is een contra-
indicatie voor transplantatie.
Ten slotte heeft de introductie van sterke immunosuppressieve medicatie een groot effect 
gehad op de uitkomst van transplantaties. Door deze medicatie werd het mogelijk organen 
van (gedeeltelijk) niet gematchte donoren toch succesvol te transplanteren. De huidige im-
munosuppressieve medicatie werkt vooral op de cellulaire arm van het immuunsysteem. 
Afstoting kort na transplantatie kan met deze medicatie goed voorkomen of, wanneer 
nodig, behandeld worden. Helaas blijkt het gunstige effect van deze medicatie alleen de 
korte termijn overleving van het transplantaat ten goede te komen. 
Hoewel de korte termijn transplantaat overleving door verschillende ontdekkingen dus 
zeer is verbeterd, is op het gebied van de lange termijn overleving nauwelijks vooruitgang 
geboekt. Afstoting veroorzaakt door het humorale immuunsysteem lijkt hierbij een belan-
grijke rol te spelen. Deze manier van afstoting is jarenlang overschaduwd door afstoting 
veroorzaakt door het cellulaire immuunsysteem. Dankzij de krachtige onderdrukking van 
de cellulaire immuniteit met immunosuppressieve medicatie wordt meer en meer de rol 
van de humorale immuniteit duidelijk. Het exacte mechanisme van humorale afstoting is 
niet volledig bekend, evenals de beste manier van behandeling. Dit proefschrift beschrijft 
verschillende aspecten van humorale immuniteit in relatie tot orgaantransplantatie met 
als doel meer inzicht te krijgen in de behandeling en monitoring van humorale afstoting.
Allereerst wordt in hoofdstuk 1 een algemene inleiding gegeven om de verschillende 
hoofdstukken van dit proefschrift in de juiste context te plaatsen. Tevens wordt het doel 
van de beschreven studies duidelijk gemaakt. Vervolgens beschrijft het eerste deel van dit 
proefschrift het effect van verschillende immunosuppressieve medicatie op humorale im-
muniteit. Hoofdstuk 2 beschrijft het effect van vier verschillende immunosuppressieve 




kweeksysteem met B cel stimulatie via activerende reagentia met als doel het directe ef-
fect van immunosuppressieve medicijnen op B cellen te onderzoeken. In dit kweeksysteem 
zijn alle immunosuppressieve effecten te herleiden tot directe effecten op B cellen. De 
resultaten beschreven in dit hoofdstuk laten duidelijk zien dat tacrolimus en cyclosporine 
(de zogenaamde calcineurine remmers) een marginaal direct effect hebben op B cellen, 
terwijl MPA en rapamycine sterke remmende eigenschappen hebben. 
In hoofdstuk 3 hebben we gebruik gemaakt van B cellen die op een T cel afhankelijke 
manier zijn gekweekt. Hierbij is gekeken naar het effect van immunosuppressieve medi-
catie op B cellen en T cellen, en naar het effect op de activatiesignalen die T cellen geven 
als hulp aan B cellen. Het blijkt dat alle vier de geteste medicijnen in staat zijn T cel hulp 
aan B cellen te remmen, zij het in verschillende mate. Tacrolimus en cyclosporine kunnen 
alleen via hun effect op T cel hulp de humorale immuunrespons remmen, terwijl MPA en 
rapamycine zowel T cel hulp als B cellen direct remmen. Deze bevinding benadrukt tevens 
het belang van het onderdrukken van  T cel hulp om B cel responses te remmen.
Uit deze twee hoofdstukken blijkt rapamycine het medicijn te zijn met het meest brede 
immunosuppressieve effect op het humorale immuunsysteem. Uit andere studies is reeds 
gebleken dat rapamycine ook andere onderdelen van de afweer betrokken bij afstoting 
remt, terwijl het gunstige, regulerende cellen van het immuunsysteem spaart. De conclusie 
van deze hoofdstukken is dan ook dat rapamycine een geschikte kandidaat is als standaard 
immuunsuppressief medicijn na transplantatie.
De volgende twee hoofdstukken beschrijven studies met experimentele immunosup-
pressieve medicatie die mogelijkerwijs gebruikt kunnen worden om humorale afstoting te 
voorkomen of te behandelen. Hoofdstuk 4 beschrijft het effect van Intraveneuze Im-
munoglobuline (IVIg) op de activatie van zuivere B cellen. IVIg is gepoold humaan plasma 
van tenminste 1000 bloeddonoren en werd oorspronkelijk gebruikt om patiënten met 
antistof deficiëntie te behandelen, omdat het hoge concentraties antistoffen met allerlei 
specificiteiten bevat. Uit studies bij patiënten met auto-immuunziekten is gebleken dat 
IVIg ook in staat is het immuunsysteem te beïnvloeden, alhoewel de exacte manier waarop 
onduidelijk is. Door deze immuun-modulerende eigenschappen wordt IVIg tegenwoor-
dig ook gebruikt om het humorale immuunsysteem te dempen in transplantatiepatiënten. 
Omdat het mechanisme waarop IVIg het humorale immuunsysteem beïnvloedt nog steeds 
onduidelijk is hebben wij het effect van IVIg op B cellen getest. Onze studies laten zien 
dat IVIg geen direct effect heeft op enkele belangrijke B cel parameters. Wij concluderen 
hieruit dat IVIg niet direct op B cellen aangrijpt, maar via inhibitie van de eerder genoemde 
T cel hulp zijn effecten op cellen van het humorale immuunsysteem uitoefent.
Hoofdstuk 5 beschrijft het effect van het experimentele medicijn Bortezomib op B 
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cellen. Het is reeds bekend dat Bortezomib in staat is geprogrammeerde celdood te indu-
ceren in bepaalde celtypen van het immuunsysteem en mogelijkerwijs humorale afstoting 
kan onderdrukken, maar het effect op humane B cellen is nog niet eerder beschreven. 
Onze studies laten zien dat relatief lage concentraties Bortezomib B cel activatie remmen, 
hetgeen leidt tot verminderde celdeling en antilichaam productie. Het eindresultaat is 
een verminderde antistofproductie, hetgeen relevant kan zijn in de context van humorale 
afstoting. De beschreven data leveren additioneel bewijs dat bortezomib een potentiële 
kandidaat is voor het voorkomen en behandelen van humorale afstoting.
Het tweede deel van dit proefschrift beschrijft manieren om het immuunsysteem van 
patiënten na transplantatie te monitoren. Dit is van groot belang om de dosis van immuno-
suppressieve medicijnen zo laag mogelijk te houden, en zo bijwerkingen te minimaliseren. 
Momenteel bestaan er weinig bruikbare technieken om de cellen van het humorale im-
muunsysteem te monitoren. In hoofdstuk 6 beschrijven we een nieuw ontwikkelde 
techniek om de frequentie van B cellen die specifiek gericht zijn tegen de donor te kwanti-
ficeren. Deze zeer gevoelige techniek stelt ons in staat zeer lage aantallen B cellen gericht 
tegen de donor per miljoen B cellen te detecteren. Met behulp van deze techniek verwa-
chten we humorale afstoting vroeg op te kunnen sporen, waardoor adequate behandeling 
mogelijk is. 
Zoals gezegd is T cel hulp van groot belang voor de activatie van B cellen. Kort na trans-
plantatie herkennen T cellen complete cellen van het immuunsysteem van de donor die 
mee zijn getransplanteerd (directe herkenning). Lang na transplantatie zijn immuuncellen 
van de donor opgeruimd en zullen de T cellen moleculen van het getransplanteerde or-
gaan alleen nog maar herkennen op receptoren van lichaamseigen cellen, net zoals bij een 
infectie met een virus of bacterie (indirecte herkenning). De frequentie van deze indirect 
herkennende T cellen is heel erg laag en daarom zijn deze cellen moeilijk te traceren. 
Hoofdstuk 7 beschrijft de problemen waar men tegenaan loopt bij het monitoren van 
deze T cellen. Vele wetenschappers beweren technieken te hebben ontwikkeld voor het 
kwantificeren van indirect herkennende T cellen, maar essentiële controles missen vaak. 









3H-TdR  3H-tritiated thymidine
3P  Third party
aa  Amino acid
ADCC  Antibody dependent cytotoxicity
APCs  Antigen presenting cells
ATG  Anti-thymocyte globulin
BCPF  B cell precursor frequency
BCR  B cell receptor
B-LCL  B lymphoblastoid cell line
BOS  Bronchiolitis obliterans syndrome
bp  Base pairs
BSA  Bovine serum albumin
CAN  Chronic allograft nephropathy
CBA  Cytometric bead array
CDC  Complement dependent cytotoxicity
CFSE  Carboxyfluorescein succinimidyl ester
CTL  Cytotoxic T lymphocyte
CTLp  Cytotoxic T lymphocyte precursor
CpG DNA Cytosine-guanine dinucleotide oligodeoxynucleotide
CPM  Counts per minute
CyP  Cyclophilin
DAR  Direct allorecognition
DC  Dendritic cell 
DMSO  Dimethyl sulfoxide
DNA  Deoxyribonucleic acid
EDTA  Ethylenediaminetetraacetic acid
ELISA  Enzyme-linked immunosorbent assay
ELISPOT Enzyme-linked immunosorbent spot
Fab  Fragment antigen-binding 
Fc  Fragment crystallizable
FcR  Fc receptor
FcRn  Neonatal Fc receptor
FCS  Fetal calf serum
FCCS  Flow cytometry cytokine secretion assay
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FCM  Flow cytometric analysis
FDC  Follicular dendritic cell
FKBP  FK506-binding protein
Foxp3  Forkhead box P3
HLA  Human leukocyte antigen
HPLC  High performance liquid chromatography
IAR  Indirect allorecognition
ICOS  Inducible costimulator
IFN-γ  Interferon-γ




IMDM  Iscove’s modified Dulbecco’s medium
IMPDH  Inosine-5’-monophosphate dehydrogenase
IVIg  Intravenous immunoglobulin
LDA  Limiting dilution analysis
LDH  Lactate dehydrogenase
mAb  Monoclonal antibody
MFI  Mean fluorescence intensity 
MHC  Major histocompatibility complex
MLC  Mixed lymphocyte culture
MMF  Mycophenolate mofetil
MPA  Mycophenolic acid
mRNA  Messenger RNA
mTOR  Mamalian target of rapamycin
NFAT  Nuclear factor of activated T cells
NF-κB  Nuclear factor-κB 
NK cell  Natural killer cell
PBMC  Peripheral blood mononuclear cells
PBS  Phosphate buffered saline
PCR  Polymerase chain reaction
PEG  Polyethylene glycol
PHA  Phytohaemagglutinin
PMSF  Phenylmethylsulphonyl fluoride
PWM  Pokeweed mitogen
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PI  Propidium Iodide
PRA  Panel reactive antibodies
PTC  Peritubular capillary
Q-PCR  Quantitative polymerase chain reaction
RhD  Rhesus D
RIA  Radioimmunoassay
RNA  Ribonucleic acid
RPMI  Roswell Park Memorial Institute medium
RT  Room temperature
RT-AMV Reverse transcriptase-avian myeloblastosis virus
SAL  Single antigen line
TCL  T cell line
TCC  T cell clone
TCR  T cell receptor
Th  T helper
TLR  Toll like receptor
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